CN115043842A - Amino-substituted bicyclic inhibitor and preparation method and application thereof - Google Patents
Amino-substituted bicyclic inhibitor and preparation method and application thereof Download PDFInfo
- Publication number
- CN115043842A CN115043842A CN202110257196.2A CN202110257196A CN115043842A CN 115043842 A CN115043842 A CN 115043842A CN 202110257196 A CN202110257196 A CN 202110257196A CN 115043842 A CN115043842 A CN 115043842A
- Authority
- CN
- China
- Prior art keywords
- group
- alkyl
- membered
- cycloalkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 239000003112 inhibitor Substances 0.000 title abstract description 44
- 150000001875 compounds Chemical class 0.000 claims abstract description 138
- 108700022176 SOS1 Proteins 0.000 claims abstract description 25
- 102000057028 SOS1 Human genes 0.000 claims abstract description 25
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 claims abstract description 23
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 claims abstract description 23
- 101150100839 Sos1 gene Proteins 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 19
- -1 nitro, hydroxy Chemical group 0.000 claims description 140
- 125000000623 heterocyclic group Chemical group 0.000 claims description 99
- 125000005843 halogen group Chemical group 0.000 claims description 80
- 229910052739 hydrogen Inorganic materials 0.000 claims description 70
- 239000001257 hydrogen Substances 0.000 claims description 70
- 125000000217 alkyl group Chemical group 0.000 claims description 66
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 62
- 229910052805 deuterium Inorganic materials 0.000 claims description 62
- 125000003118 aryl group Chemical group 0.000 claims description 61
- 229910052736 halogen Inorganic materials 0.000 claims description 51
- 150000002367 halogens Chemical class 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 48
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 46
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 42
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 41
- 238000006467 substitution reaction Methods 0.000 claims description 37
- 125000004043 oxo group Chemical group O=* 0.000 claims description 33
- 125000003545 alkoxy group Chemical group 0.000 claims description 30
- 239000012453 solvate Substances 0.000 claims description 29
- 150000001412 amines Chemical class 0.000 claims description 28
- 229940124530 sulfonamide Drugs 0.000 claims description 28
- 150000003456 sulfonamides Chemical class 0.000 claims description 28
- 150000002148 esters Chemical class 0.000 claims description 27
- 125000002947 alkylene group Chemical group 0.000 claims description 26
- 150000001408 amides Chemical class 0.000 claims description 26
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 26
- 229940002612 prodrug Drugs 0.000 claims description 25
- 239000000651 prodrug Substances 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 23
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 21
- 239000004202 carbamide Substances 0.000 claims description 19
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 18
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 125000005189 alkyl hydroxy group Chemical group 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000013078 crystal Substances 0.000 claims description 7
- 125000006413 ring segment Chemical group 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 6
- 150000004677 hydrates Chemical class 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000003368 amide group Chemical group 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 125000004185 ester group Chemical group 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000012442 inert solvent Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 125000000565 sulfonamide group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 229940126271 SOS1 inhibitor Drugs 0.000 abstract description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 63
- 239000000243 solution Substances 0.000 description 35
- 125000000392 cycloalkenyl group Chemical group 0.000 description 27
- 125000001424 substituent group Chemical group 0.000 description 27
- 239000000047 product Substances 0.000 description 26
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 229940079593 drug Drugs 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 17
- 125000001072 heteroaryl group Chemical group 0.000 description 17
- 125000003342 alkenyl group Chemical group 0.000 description 15
- 102100030708 GTPase KRas Human genes 0.000 description 13
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 125000000304 alkynyl group Chemical group 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 239000002525 vasculotropin inhibitor Substances 0.000 description 10
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 125000000547 substituted alkyl group Chemical group 0.000 description 9
- 125000003107 substituted aryl group Chemical group 0.000 description 9
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 125000004104 aryloxy group Chemical group 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 5
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical group C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 125000002993 cycloalkylene group Chemical group 0.000 description 5
- 125000005265 dialkylamine group Chemical group 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 102200006538 rs121913530 Human genes 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- PFTBUSKWFDVYMM-CONDHPEXSA-N 1,3,5-tris[(e)-2-(3,5-didecoxyphenyl)ethenyl]benzene Chemical compound CCCCCCCCCCOC1=CC(OCCCCCCCCCC)=CC(\C=C\C=2C=C(\C=C\C=3C=C(OCCCCCCCCCC)C=C(OCCCCCCCCCC)C=3)C=C(\C=C\C=3C=C(OCCCCCCCCCC)C=C(OCCCCCCCCCC)C=3)C=2)=C1 PFTBUSKWFDVYMM-CONDHPEXSA-N 0.000 description 4
- FQXOOGHQVPKHPG-UHFFFAOYSA-N 1,3-diazinane-2,4,5-trione Chemical compound O=C1NCC(=O)C(=O)N1 FQXOOGHQVPKHPG-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 101100421901 Caenorhabditis elegans sos-1 gene Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 206010069755 K-ras gene mutation Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229950001290 lorlatinib Drugs 0.000 description 4
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
- QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical group C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229960001686 afatinib Drugs 0.000 description 3
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 229950004272 brigatinib Drugs 0.000 description 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940121647 egfr inhibitor Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960002584 gefitinib Drugs 0.000 description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000002560 nitrile group Chemical group 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 229960003787 sorafenib Drugs 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 229960005267 tositumomab Drugs 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- SADXACCFNXBCFY-IYNHSRRRSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2r)-1-methylpyrrolidin-2-yl]prop-2-enamide Chemical compound C=12C=C(NC(=O)\C=C\[C@@H]3N(CCC3)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 SADXACCFNXBCFY-IYNHSRRRSA-N 0.000 description 2
- WIWZBGUEDUUYBD-UHFFFAOYSA-N 1-cyclopropyl-3-methylurea Chemical compound CNC(=O)NC1CC1 WIWZBGUEDUUYBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 description 2
- SPYLLSKIPZGXNM-RXMQYKEDSA-N 3-[(1R)-1-aminoethyl]-5-(trifluoromethyl)aniline Chemical compound C[C@@H](N)c1cc(N)cc(c1)C(F)(F)F SPYLLSKIPZGXNM-RXMQYKEDSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- UWDMKTDPDJCJOP-UHFFFAOYSA-N 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ium-4-carboxylate Chemical compound CC1(C)CC(O)(C(O)=O)CC(C)(C)N1 UWDMKTDPDJCJOP-UHFFFAOYSA-N 0.000 description 2
- ADGGYDAFIHSYFI-UHFFFAOYSA-N 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1 ADGGYDAFIHSYFI-UHFFFAOYSA-N 0.000 description 2
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 240000004178 Anthoxanthum odoratum Species 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 2
- 229940124291 BTK inhibitor Drugs 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000005461 Canertinib Substances 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 2
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 2
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 2
- WLLGXSLBOPFWQV-UHFFFAOYSA-N MGK 264 Chemical compound C1=CC2CC1C1C2C(=O)N(CC(CC)CCCC)C1=O WLLGXSLBOPFWQV-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- MWEPUUMUAIDGJD-UHFFFAOYSA-N NC1=CC(N(C(N1C)=O)C1CC1)=O Chemical compound NC1=CC(N(C(N1C)=O)C1CC1)=O MWEPUUMUAIDGJD-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 239000012270 PD-1 inhibitor Substances 0.000 description 2
- 239000012668 PD-1-inhibitor Substances 0.000 description 2
- 239000012271 PD-L1 inhibitor Substances 0.000 description 2
- 239000012828 PI3K inhibitor Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102000005588 Son of Sevenless Proteins Human genes 0.000 description 2
- 108010059447 Son of Sevenless Proteins Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000005529 alkyleneoxy group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 229940070173 bimiralisib Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004305 biphenyl Chemical group 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 229950003628 buparlisib Drugs 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229950002826 canertinib Drugs 0.000 description 2
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 2
- 125000002837 carbocyclic group Chemical class 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- 125000005366 cycloalkylthio group Chemical group 0.000 description 2
- 229950002205 dacomitinib Drugs 0.000 description 2
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 2
- 229950006418 dactolisib Drugs 0.000 description 2
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 229950004949 duvelisib Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011737 fluorine Chemical group 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 2
- 229960001507 ibrutinib Drugs 0.000 description 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 2
- 229950007440 icotinib Drugs 0.000 description 2
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 2
- 229960003445 idelalisib Drugs 0.000 description 2
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- AIFMMWUXXYXRAO-UHFFFAOYSA-N methyl 2-chloro-1-methyl-6-oxopyridine-3-carboxylate Chemical compound COC(=O)C=1C=CC(=O)N(C)C=1Cl AIFMMWUXXYXRAO-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 229960002450 ofatumumab Drugs 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 description 2
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 2
- 229950010773 pidilizumab Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 238000004237 preparative chromatography Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229940075576 pyrotinib Drugs 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229940121497 sintilimab Drugs 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229950001269 taselisib Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- RZBQSBXQOWBINI-RXMQYKEDSA-N (1R)-1-[3-nitro-5-(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@@H](N)c1cc(cc(c1)C(F)(F)F)[N+]([O-])=O RZBQSBXQOWBINI-RXMQYKEDSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical group CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- RNHWYOLIEJIAMV-UHFFFAOYSA-N 1-chlorotetradecane Chemical class CCCCCCCCCCCCCCCl RNHWYOLIEJIAMV-UHFFFAOYSA-N 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical class CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
- ZAPWNCMJTXAINY-UHFFFAOYSA-N 2-chloro-1-methyl-6-oxopyridine-3-carboxylic acid Chemical compound CN1C(Cl)=C(C(O)=O)C=CC1=O ZAPWNCMJTXAINY-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical class OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- GZLZRPNUDBIQBM-UHFFFAOYSA-N 6-amino-1-methylpyrimidine-2,4-dione Chemical compound CN1C(N)=CC(=O)NC1=O GZLZRPNUDBIQBM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 101100096578 Arabidopsis thaliana SQD2 gene Proteins 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- WWCNXHYRAKUQDB-SNVBAGLBSA-N [(3r)-oxolan-3-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)O[C@H]1COCC1 WWCNXHYRAKUQDB-SNVBAGLBSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical class BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- WRXDGGCKOUEOPW-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)NS(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 WRXDGGCKOUEOPW-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N deuterated acetone Substances [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 125000005612 glucoheptonate group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 102000009543 guanyl-nucleotide exchange factor activity proteins Human genes 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004966 intestinal stem cell Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 1
- HUFOZJXAKZVRNJ-UHFFFAOYSA-N n-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCN(CC2)C(C)=O)=CC=C1NC(N=1)=NC=C(C(F)(F)F)C=1NC1=CC=CC(NC(=O)C=C)=C1 HUFOZJXAKZVRNJ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- TUIAQSKEFHFDRQ-UHFFFAOYSA-N n-chloro-n-methylformamide Chemical compound CN(Cl)C=O TUIAQSKEFHFDRQ-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000005959 oncogenic signaling Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical class CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229950009855 rociletinib Drugs 0.000 description 1
- 102200006531 rs121913529 Human genes 0.000 description 1
- 102200006539 rs121913529 Human genes 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an amino-substituted bicyclic inhibitor and a preparation method and application thereof. The compound has a structure shown in a formula (I), and also discloses a preparation method of the compound and application of the compound as an SOS1 inhibitor, wherein the compound has a good selective inhibition effect on SOS1, and has better pharmacodynamics and pharmacokinetic properties and lower toxic and side effects.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to an amino-substituted bicyclic inhibitor, and a preparation method and application thereof.
Background
Lung cancer is one of the leading causes of death in human cancers. Lung cancer can be divided into Small Cell Lung Cancer (SCLC) and non-small cell lung cancer (NSCLC) according to cell type, with NSCLC accounting for 85% of all lung cancer patients. The market for NSCLC worldwide was statistically about $ 209 million in 2016, with the U.S. market half as much, followed by japan, germany, and china. From the current trend, the market for non-small cell lung cancer is continuing to grow, and the global market is expected to reach $ 540 billion in 2023 (Nature, 2018; 553(7689):446- > 454).
At present, the main therapeutic drugs of NSCLC include chemotherapeutic drugs, molecular targeted drugs, tumor immunotherapy and the like. The chemotherapy drugs mainly comprise gemcitabine, paclitaxel, platinum drugs and the like, but the drugs generally have poor selectivity and high toxicity, so that relatively strong toxic and side effects are caused. In recent years, molecular targeted drugs have become research hotspots due to the obvious advantages of high selectivity, relatively small toxic and side effects, accurate treatment and the like. Existing molecular targeted drugs for NSCLC include EGFR inhibitors (such as Afatinib, Gefitinib, Erlotinib, Lapatinib, Dacomitinib, Icotinib, Pyrotinib, Rociletinib, Osimetinib, etc.), ALK inhibitors (such as Ceritinib, Alectoib, Brigatinib, Lorlatinib, Ocatinib, etc.), and VEGFR inhibitors (Sorafenib, Regorafenib, Cabozantinib, Sunitinib, Dunalinib, etc.) (Current medical Chemistry,2019,26, 1-39).
KRAS mutations occur in 20-40% of lung adenocarcinomas, with a higher prevalence in western (vs asia) populations (26% vs 11%) and in smokers (vs non-smokers) (30% vs 10%). The most common mutations occur in codons 12 and 13, the most common mutations include G12C, G12V, and G12D. To date, no drug against KRAS mutations has been approved for marketing in the market.
Within the cell, the KRAS protein transitions between an inactive and an active state, when KRAS is bound to Guanosine Diphosphate (GDP), it is in the inactive state, when it is bound to Guanosine Triphosphate (GTP), it is in the active state, and downstream signaling pathways can be activated. The transition of KRAS between inactive and active states is regulated by two types of factors. One class is guanine nucleotide exchange factor (GEF), which catalyzes the binding of KRAS to GTP, thereby promoting KRAS activation, including the SOS1 protein. Another class is the Gtpase Activator Proteins (GAPs), which promote the hydrolysis of KRAS-bound GTP to GDP, thereby inhibiting KRAS activity.
To date, three major RAS-specific GEFs have been identified, with SOS proteins being primarily found in tumors. SOS proteins are widely expressed in vivo and contain two isoforms SOS1 and SOS 2. Published data indicate that SOS1 plays a key role in mutant KRAS activation and oncogenic signaling. A decrease in the level of SOS1 resulted in a decrease in the proliferation and survival of tumor cells carrying the KRAS mutation, whereas KRAS wild-type cell lines were not affected. The effect of the loss of SOS1 could not be rescued by introducing a SOS1 mutated at the catalytic site, suggesting an important role for SOS1 GEF activity in KRAS mutant cancer cells (see WO2019122129a 1).
Since KRAS binding to GTP, whether mutated or wild-type, is dependent on SOS1, selective inhibition of SOS1, whether mutated or not, prevents interaction of SOS1 with KRAS and ultimately inhibits KRAS activation.
Since the SOS1 target protein is pathologically associated with a variety of diseases, there is also a need for novel SOS1 inhibitors for clinical therapy. The SOS1 inhibitor with high selectivity and high activity can be used for more effectively treating diseases such as cancers caused by KRAS mutation and reducing the potential of off-target effect, so that the clinical demand is more urgent.
Disclosure of Invention
The invention aims to provide a novel compound with selective SOS1 inhibition effect and/or better pharmacodynamic property and application thereof.
In a first aspect of the present invention, there is provided a compound having the structure of formula (I), a stereoisomer, a tautomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof:
in the formula:
ring A and ring B are each independently a 5-7 membered ring, and at least one ring atom in ring A or ring B is a heteroatom;
R 1 selected from the group consisting of substituted or unsubstituted: c 3 -C 18 Cycloalkyl, 4-20 membered heterocyclyl, C 6 -C 14 Aryl, 5-14 membered heteroaryl;
R 2 selected from the group consisting of substituted or unsubstituted: c 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl or 4-6 membered heterocyclyl;
r and R', which are the same or different, are each independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, oxo, - (CH) 2 ) m R 8 、-(CH 2 ) m (CH=CH)R 8 、-(CH 2 ) m (C≡C)R 8 、-(CH 2 ) m O(CH 2 ) p R 8 、-(CH 2 ) m SR 8 、-(CH 2 ) m COR 8 、-(CH 2 ) m C(O)OR 8 、-(CH 2 ) m S(O) q R 8 、-(CH 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m S(O) q NR 8 R 9 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In which, CH 2 H in (a) may be optionally substituted;
R 8 、R 9 and R 10 Each independently selected from the group consisting of substituted or unsubstituted: hydrogen, C 1 -C 18 Alkyl radical, C 3 -C 20 Cycloalkyl, 4-20 membered heterocyclyl, R 11 -(C 3 -C 20 Cycloalkylene radical C 1 -C 18 Alkylene) -, R 11 - (4-to 20-membered heterocycloalkylene C) 1 -C 18 Alkylene) -, - (C) 3 -C 20 Cycloalkylene radical C 1 -C 18 Alkylene) -R 11 - (4-to 20-membered heterocycloalkylene C) 1 -C 18 Alkylene) -R 11 ;
Or in- (CH) 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m S(O) q NR 8 R 9 In, R 8 And R 9 And the adjacent N atom thereof form a substituted or unsubstituted 4-8 membered heterocyclic group; or in- (CH) 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In, R 8 And R 9 Is cyclized with its adjacent N atom to form a substituted or unsubstituted 4-8 membered heterocyclic group, or R 8 And R 10 Ring-closing with its adjacent atom to form a substituted or unsubstituted 4-8 membered heterocyclic group;
R 11 selected from the group consisting of: hydrogen, deuterium, C 1 -C 18 Alkyl, deuterated C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl hydroxy, C 3 -C 20 Cycloalkyl radical, C 1 -C 18 Alkoxy, deuterated C 1 -C 18 Alkoxy, halo C 1 -C 18 Alkoxy radical, C 3 -C 20 Cycloalkyl oxy, C 6 -C 14 Aryl, 5-14 membered heteroaryl, 4-20 membered heterocyclyl, C 6 -C 14 Aryloxy, 5-14 membered heteroaryloxy, 4-20 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea;
wherein the above substitution means substitution with one or more groups selected from the group consisting of: hydrogen, deuterium, C 1 -C 18 Alkyl, deuterated C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl radicalHydroxy, C 3 -C 20 Cycloalkyl radical, C 1 -C 18 Alkoxy, deuterated C 1 -C 18 Alkoxy, halo C 1 -C 18 Alkoxy radical, C 3 -C 20 Cycloalkyloxy radical, C 6 -C 14 Aryl, 5-14 membered heteroaryl, 4-20 membered heterocyclyl, C 6 -C 14 Aryloxy, 5-14 membered heteroaryloxy, 4-20 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea;
m is 0, 1,2,3,4, 5 or 6;
p is 0, 1,2,3,4, 5 or 6;
q is 1 or 2;
u is 0, 1,2 or 3;
t is 0, 1,2,3 or 4;
In another preferred embodiment, at least one ring atom of ring a or ring B is N.
In another preferred embodiment, 1 to 5 (i.e., 1,2,3,4, 5) ring atoms in ring a or ring B are N.
In another preferred embodiment, the 5-7 membered ring is selected from: 5-7 membered heterocyclic group, 5-7 membered heteroaryl group, C 5 -C 7 And (4) an aryl group.
In another preferred embodiment, ring a and ring B are each independently 6-membered heterocyclyl, 6-membered heteroaryl, phenyl.
In another preferred embodiment, R 8 、R 9 And R 10 Each independently selected from the group consisting of substituted or unsubstituted: hydrogen, C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl, R 11 -(C 3 -C 6 Cycloalkylene radical C 1 -C 6 Alkylene) -, R 11 - (4-to 6-membered heterocycloalkylene C) 1 -C 6 Alkylene) -, - (C) 3 -C 6 Cycloalkylene radical C 1 -C 6 Alkylene) -R 11 - (4-to 6-membered heterocycloalkylene C) 1 -C 6 Alkylene) -R 11 ;
R 11 Selected from: hydrogen, deuterium, C 1 -C 6 Alkyl, deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 3 -C 6 Cycloalkyl radical, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy radical, C 3 -C 6 Cycloalkyl oxy, C 6 -C 10 Aryl, 5-10 membered heteroaryl, 4-6 membered heterocyclyl, C 6 -C 10 Aryloxy, 5-to 10-membered heteroaryloxy, 4-to 6-membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea.
In another preferred embodiment, the compound, its stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug has the structure shown in formula (I'):
in the formula:
R 1 selected from the group consisting of substituted or unsubstituted: c 3 -C 18 Cycloalkyl, 4-20 membered heterocyclyl, C 6 -C 14 Aryl, 5-14 membered heteroaryl;
R 2 selected from the group consisting of substituted or unsubstituted: c 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl or 4-6 membered heterocyclyl;
X 1 、X 2 、X 3 、X 4 、X 5 、X 6 、X 7 、X 8 and X 9 Each independently selected from: C. CR 3 、CO、N、NR 4 、SO 2 Or CR 3 R 5 (ii) a Wherein X 1 、X 2 、X 3 、X 4 、X 5 、X 6 、X 7 、X 8 And X 9 At least one of which contains a heteroatom;
R 3 identical or different, each independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, - (CH) 2 ) m R 8 、-(CH 2 ) m (CH=CH)R 8 、-(CH 2 ) m (C≡C)R 8 、-(CH 2 ) m O(CH 2 ) p R 8 、-(CH 2 ) m SR 8 、-(CH 2 ) m COR 8 、-(CH 2 ) m C(O)OR 8 、-(CH 2 ) m S(O) q R 8 、-(CH 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m S(O) q NR 8 R 9 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In which, CH 2 H in (a) may be optionally substituted;
R 5 the same or different, each independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, - (CH) 2 ) m R 8 、-(CH 2 ) m (CH=CH)R 8 、-(CH 2 ) m (C≡C)R 8 、-(CH 2 ) m O(CH 2 ) p R 8 、-(CH 2 ) m SR 8 、-(CH 2 ) m COR 8 、-(CH 2 ) m C(O)OR 8 、-(CH 2 ) m S(O) q R 8 、-(CH 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m S(O) q NR 8 R 9 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In which, CH 2 H in (a) may be optionally substituted;
R 4 identical or different, each independently selected from the group consisting of: hydrogen, deuterium, - (CH) 2 ) m R 8 、-(CH 2 ) m (CH=CH)R 8 、-(CH 2 ) m (C≡C)R 8 、-(CH 2 ) m O(CH 2 ) p R 8 、-(CH 2 ) m SR 8 、-(CH 2 ) m COR 8 、-(CH 2 ) m C(O)OR 8 、-(CH 2 ) m S(O) q R 8 、-(CH 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m S(O) q NR 8 R 9 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In which, CH 2 H in (a) may be optionally substituted;
R 8 、R 9 and R 10 Each independently selected from the group consisting of substituted or unsubstituted: hydrogen, C 1 -C 18 Alkyl radical, C 3 -C 20 Cycloalkyl, 4-20 membered heterocyclyl, R 11 -(C 3 -C 20 Cycloalkylene radical C 1 -C 18 Alkylene) -, R 11 - (4-to 20-membered heterocycloalkylene C) 1 -C 18 Alkylene) -, - (C) 3 -C 20 Cycloalkylene radical C 1 -C 18 Alkylene) -R 11 - (4-to 20-membered heterocycloalkylene C) 1 -C 18 Alkylene) -R 11 ;
Or in- (CH) 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m S(O) q NR 8 R 9 In, R 8 And R 9 And the adjacent N atom thereof form a substituted or unsubstituted 4-8 membered heterocyclic group; or in- (CH) 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In, R 8 And R 9 Is cyclized with its adjacent N atom to form a substituted or unsubstituted 4-8 membered heterocyclic group, or R 8 And R 10 And the adjacent atoms are cyclized to form a substituted or unsubstituted 4-8 membered heterocyclic group;
R 11 selected from: hydrogen, deuterium, C 1 -C 18 Alkyl, deuterated C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl hydroxy, C 3 -C 20 Cycloalkyl radical, C 1 -C 18 Alkoxy, deuterated C 1 -C 18 Alkoxy, halo C 1 -C 18 Alkoxy radical, C 3 -C 20 Cycloalkyloxy radical, C 6 -C 14 Aryl, 5-14 membered heteroaryl, 4-20 membered heterocyclyl, C 6 -C 14 Aryloxy, 5-14 membered heteroaryloxy, 4-20 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea;
wherein the above substitution means substitution with one or more groups selected from the group consisting of: hydrogen, deuterium, C 1 -C 18 Alkyl, deuterationC 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl hydroxy, C 3 -C 20 Cycloalkyl radical, C 1 -C 18 Alkoxy, deuterated C 1 -C 18 Alkoxy, halo C 1 -C 18 Alkoxy radical, C 3 -C 20 Cycloalkyl oxy, C 6 -C 14 Aryl, 5-14 membered heteroaryl, 4-20 membered heterocyclyl, C 6 -C 14 Aryloxy, 5-14 membered heteroaryloxy, 4-20 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea;
m is 0, 1,2,3,4, 5 or 6;
p is 0, 1,2,3,4, 5 or 6;
q is 1 or 2;
In another preferred embodiment, X 1 、X 2 、X 3 、X 4 、X 5 、X 6 、X 7 、X 8 And X 9 At least one of which is N.
In another preferred embodiment, R 2 Is methyl.
In another preferred embodiment, in formulas I and I', the compound, stereoisomer, tautomer, crystalline form, pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof has the structure shown in formula (II):
in the formula, R 1 、X 1 、X 2 、X 3 、X 4 、X 5 、X 6 、X 7 、X 8 And X 9 Is as defined above.
In another preferred embodiment, R 1 Selected from the group consisting of substituted or unsubstituted: c 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl, phenyl, 5-10 membered heteroaryl;
wherein, the substitution refers to the substitution by one or more (such as 2,3, 4) groups selected from the following group: hydrogen, deuterium, C 1 -C 6 Alkyl, deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 3 -C 6 Cycloalkyl radical, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy radical, C 3 -C 6 Cycloalkyloxy, 4-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl, phenyloxy, 5-6 membered heteroaryloxy, 4-6 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea.
In another preferred embodiment, the compound, its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, wherein,moieties are selected from:
in the formula (I), the compound is shown in the specification,
R 3a -R 3f the same or different, each independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, - (CH) 2 ) m R 8 、-(CH 2 ) m (CH=CH)R 8 、-(CH 2 ) m (C≡C)R 8 、-(CH 2 ) m O(CH 2 ) p R 8 、-(CH 2 ) m SR 8 、-(CH 2 ) m COR 8 、-(CH 2 ) m C(O)OR 8 、-(CH 2 ) m S(O) q R 8 、-(CH 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m S(O) q NR 8 R 9 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In which CH 2 H in (a) may be optionally substituted;
R 4a -R 4b the same or different, each independently selected from the group consisting of: hydrogen, deuterium, - (CH) 2 ) m R 8 、-(CH 2 ) m (CH=CH)R 8 、-(CH 2 ) m (C≡C)R 8 、-(CH 2 ) m O(CH 2 ) p R 8 、-(CH 2 ) m SR 8 、-(CH 2 ) m COR 8 、-(CH 2 ) m C(O)OR 8 、-(CH 2 ) m S(O) q R 8 、-(CH 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m S(O) q NR 8 R 9 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In which CH 2 H in (a) may be optionally substituted;
R 5b -R 5c the same or different, each independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, - (CH) 2 ) m R 8 、-(CH 2 ) m (CH=CH)R 8 、-(CH 2 ) m (C≡C)R 8 、-(CH 2 ) m O(CH 2 ) p R 8 、-(CH 2 ) m SR 8 、-(CH 2 ) m COR 8 、-(CH 2 ) m C(O)OR 8 、-(CH 2 ) m S(O) q R 8 、-(CH 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m S(O) q NR 8 R 9 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In which CH 2 H in (a) may be optionally substituted;
wherein the above substitution means substitution by a group selected from the group consisting of: hydrogen, deuterium, C 1 -C 18 Alkyl, deuterated C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl hydroxy, C 3 -C 20 Cycloalkyl, C 1 -C 18 Alkoxy, deuterated C 1 -C 18 Alkoxy, halo C 1 -C 18 Alkoxy radical, C 3 -C 20 Cycloalkyloxy radical, C 6 -C 14 Aryl, 5-14 membered heteroaryl, 4-20 membered heterocyclyl, C 6 -C 14 Aryloxy, 5-14 membered heteroaryloxy, 4-20 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea;
wherein R is 8 、R 9 、R 10 M, p and q are as defined above.
in the formula (I), the compound is shown in the specification,
R 5d selected from the group consisting of substituted or unsubstituted: hydrogen, deuterium, halogen, cyano, - (CH) 2 ) m R 8 、-(CH 2 ) m (CH=CH)R 8 、-(CH 2 ) m (C≡C)R 8 、-(CH 2 ) m O(CH 2 ) p R 8 、-(CH 2 ) m SR 8 、-(CH 2 ) m COR 8 、-(CH 2 ) m C(O)OR 8 、-(CH 2 ) m S(O) q R 8 、-(CH 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m S(O) q NR 8 R 9 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In which, CH 2 H in (b) may be optionally substituted, said substitution being with a group selected from the group consisting of: hydrogen, deuterium, C 1 -C 18 Alkyl, deuterated C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl hydroxy, C 3 -C 20 Cycloalkyl, C 1 -C 18 Alkoxy, deuterated C 1 -C 18 Alkoxy, halo C 1 -C 18 Alkoxy radical, C 3 -C 20 Cycloalkyl oxy, C 6 -C 14 Aryl, 5-14 membered heteroaryl, 4-20 membered heterocyclyl, C 6 -C 14 Aryloxy, 5-14 membered heteroaryloxy, 4-20 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea;
R 3a -R 3f 、R 4a -R 4b 、R 5b -R 5c 、R 8 、R 9 、R 10 m, p and q are as defined above.
in the formula, R 3a -R 3f 、R 4a -R 4b Is as defined above.
in the formula, R 3a -R 3f 、R 4a -R 4b Is as defined above.
In another preferred embodiment, R 3a -R 3f Each independently selected from the group consisting of substituted or unsubstituted: hydrogen, deuterium, C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl, C 3 -C 6 Cycloalkyl radical C 1 -C 6 Alkylene, 4-to 6-membered heterocycloalkyl C 1 -C 6 Alkylene, -O-C 1 -C 6 Alkyl, -O-C 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl-O-, C 3 -C 6 Cycloalkyl radical C 1 -C 6 alkylene-O-, 4-6 membered heterocycloalkyl C 1 -C 6 alkylene-O-, -O- (CH) 2 ) w C 1 -C 6 Alkoxy radical, R 12 -(C 3 -C 6 Cycloalkylene radical C 1 -C 6 Alkylene) -, R 12 - (4-to 6-membered heterocycloalkylene C) 1 -C 6 Alkylene) -, - (C) 3 -C 6 Cycloalkylene radical C 1 -C 6 Alkylene) -R 12 - (4-to 6-membered heterocycloalkylene C) 1 -C 6 Alkylene) -R 12 (ii) a Wherein w is 1,2,3 or 4;
wherein R is 12 Selected from: hydrogen, deuterium, C 1 -C 6 Alkyl, deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 3 -C 6 Cycloalkyl radical, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy radical, C 3 -C 6 Cycloalkyl oxy, C 6 -C 10 Aryl, 5-10 membered heteroaryl, 4-6 membered heterocyclyl, C 6 -C 10 Aryloxy, 5-10 membered heteroaryloxy, 4-6 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea;
wherein said substitution means substitution by one or more groups selected from the group consisting of: deuterium, C 1 -C 6 Alkyl, deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy, halogen, oxo, nitro, hydroxyl, cyano, ester, amine, amide, sulfonamide, or urea groups.
In another preferred embodiment, R 4a -R 4b Each independently selected from the group consisting of substituted or unsubstituted: hydrogen, C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl, C 3 -C 6 Cycloalkyl radical C 1 -C 6 Alkylene, 4-to 6-membered heterocycloalkyl C 1 -C 6 An alkylene group; wherein said substitution is by one or more groups selected from the group consisting of: deuterium, C 1 -C 6 Alkyl, deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy radical, R 12 -(C 3 -C 6 Cycloalkylene radical C 1 -C 6 Alkylene) -, R 12 - (4-to 6-membered heterocycloalkylene C) 1 -C 6 Alkylene) -, - (C) 3 -C 6 Cycloalkylene radical C 1 -C 6 Alkylene) -R 12 - (4-to 6-membered heterocycloalkylene C) 1 -C 6 Alkylene) -R 12 Halogen, oxo, nitro, hydroxyl, cyano, ester, amino, amido, sulfonamide, or ureido;
wherein R is 12 Selected from: hydrogen, deuterium, C 1 -C 6 Alkyl, deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 3 -C 6 Cycloalkyl radical, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy radical, C 3 -C 6 Cycloalkyl oxy, C 6 -C 10 Aryl, 5-10 membered heteroaryl, 4-6 membered heterocyclyl, C 6 -C 10 Aryloxy, 5-10 membered heteroaryloxy, 4-6 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea; .
In another preferred embodiment, R 5b -R 5c Each independently selected from the group consisting of substituted or unsubstituted: hydrogen, deuterium, C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl, C 3 -C 6 Cycloalkyl radical C 1 -C 6 Alkylene, 4-to 6-membered heterocycloalkyl C 1 -C 6 Alkylene, -O-C 1 -C 6 Alkyl, -O-C 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl-O-, C 3 -C 6 Cycloalkyl radical C 1 -C 6 alkylene-O-, 4-6 membered heterocycloalkyl C 1 -C 6 alkylene-O-, -O- (CH) 2 ) w C 1 -C 6 Alkoxy radical, R 12 -(C 3 -C 6 Cycloalkylene radical C 1 -C 6 Alkylene) -, R 12 - (4-to 6-membered heterocycloalkylene C) 1 -C 6 Alkylene) -, - (C) 3 -C 6 Cycloalkylene radical C 1 -C 6 Alkylene) -R 12 - (4-to 6-membered heterocycloalkylene C) 1 -C 6 Alkylene) -R 12 (ii) a Wherein w is 1,2,3 or 4;
wherein R is 12 Selected from: hydrogen, deuterium, C 1 -C 6 Alkyl, deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 3 -C 6 Cycloalkyl radical, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy radical, C 3 -C 6 Cycloalkyl oxy, C 6 -C 10 Aryl, 5-10 membered heteroaryl, 4-6 membered heterocyclyl, C 6 -C 10 Aryloxy, 5-10 membered heteroaryloxy, 4-6 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea;
wherein said substitution is by one or more groups selected from the group consisting of: deuterium, C 1 -C 6 Alkyl, deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea groups.
In another preferred embodiment, R 1 Selected from the group consisting of substituted or unsubstituted: phenyl, pyridyl, pyrimidinyl, indolyl, benzopyrazolyl, benzimidazolyl, benzothiazolyl,Wherein said substitution means substitution by one or more groups selected from the group consisting of: hydrogen, deuterium, C 1 -C 6 Alkyl, deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea groups.
In another preferred embodiment, the compound, its stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof is provided, wherein R is 1 Selected from the group consisting of:
in another preferred embodiment, ring A, ring B, R, R', R 1 、R 2 、X 1 、X 2 、X 3 、X 4 、X 5 、X 6 、X 7 、X 8 、X 9 、R 3a -R 3f 、R 4a -R 4b 、R 5b -R 5c 、R 8 、R 9 、R 10 T, u, m, p and q correspond to the groups shown for each specific compound in the examples.
In another preferred embodiment, the compound, its stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof is selected from the group consisting of:
in another preferred embodiment, the compound is selected from the compounds shown in the examples.
In a second aspect of the present invention, there is provided a process for preparing a compound having a structure of formula (I), a stereoisomer, a tautomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof, according to the first aspect, comprising the steps of:
(i) reacting a compound of formula V-1 with a compound of formula V-2 in an inert solvent in the presence of a base, a condensing agent or a Pd catalyst to obtain a compound of formula (I);
in the formula (I), the compound is shown in the specification,
x is selected from: halogen, OH, O, OTf, OTs, Oms;
R 1 、R 2 r, R', Ring A, Ring B, u and t are as defined above.
In a third aspect of the invention, there is provided a pharmaceutical composition comprising i) one or more compounds according to the first aspect, stereoisomers, tautomers, crystalline forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof; and ii) a pharmaceutically acceptable carrier.
In another preferred embodiment, the pharmaceutical composition further comprises one or more therapeutic agents selected from the group consisting of: PD-1 inhibitors (e.g., nivolumab, pembrolizumab, pidilizumab, cemipimab, JS-001, SHR-120, BGB-A317, IBI-308, GLS-010, GB-226, STW204, HX008, HLX10, BAT 1306, AK105, LZM 009, or biologically similar drugs thereof), PD-L1 inhibitors (e.g., durvalumab, atezolizumab, avelumab, CS1001, KN035, HLX20, SHR-1316, BGB-A333, JS003, CS1003, A167, F520, GR1405, MSB2311, or biologically similar drugs thereof), CD20 antibodies (e.g., rituximab, obizumab, ofatumumab, tositumomab, MSB 131, tositumomab, TSB 90, TSH-55, TSB-35, TSB-102, TSB-35, TSB-52, TSB-35, TSC-35, TSB-35, TSC-35, TSB-55, TSB-D-35, TSB-D2, TSB-D, Alectonib, Brigatinib, Lorlatinib, Ocatinib), PI3K inhibitors (e.g., Idelalisib, Duvelisib, Dactolisib, Taselisib, Bimiralisib, Omipaliib, Buparlisib, etc.), BTK inhibitors (e.g., Ibrutinib, Tirabutinib, Acalburtinib, Zanburtinib, Vecabbrutinib, etc.), EGFR inhibitors (e.g., Afatinib, Gefitinib, Erlottinib, Lapatitinib, Dacomitinib, Icotinza, Canertinib, Sapititinib, Nakutinib, Pyratinib, Rocilitinib, Osimetinib, etc.), inhibitors (e.g., Sorafenib, Pazotinib, Zoletatinib, Entinosib, Ile, Nonacitinib, Picatinib, Spinosib, Spinostinib, Spinosib, Spinosi.
In a fourth aspect of the present invention, there is provided a use of a compound of the first aspect, a stereoisomer, a tautomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof, or a pharmaceutical composition of the third aspect, for the preparation of a medicament for the prevention and/or treatment of a disease associated with i) an activity or an expression amount of SOS 1; and/or ii) SOS1 downstream signal pathway related diseases.
In another preferred embodiment, the disease is cancer.
In another preferred embodiment, the cancer is selected from: lung cancer, breast cancer, prostate cancer, esophageal cancer, colorectal cancer, bone cancer, kidney cancer, stomach cancer, liver cancer, colorectal cancer, melanoma, lymphoma, leukemia, brain tumor, myeloma, soft tissue sarcoma, pancreatic cancer, and skin cancer.
In a fifth aspect of the present invention, there is provided a method for inhibiting SOS1 activity in vitro, comprising the steps of: contacting a compound of the first aspect, a stereoisomer, a tautomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof, or a pharmaceutical composition of the third aspect, with a protein or a cell, thereby inhibiting SOS1 activity.
In another preferred embodiment, the cell is selected from the group consisting of: macrophages, intestinal cells (including intestinal stem cells, intestinal epithelial cells), or a combination thereof.
In another preferred embodiment, the cell is from a rodent (e.g., mouse, rat), or primate (e.g., human).
In a sixth aspect of the invention, there is provided a method for non-diagnostic, non-therapeutic inhibition of SOS1, comprising the steps of: administering to a subject in need thereof an effective amount of a compound of the first aspect, a stereoisomer, tautomer, crystalline form, pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, or administering a pharmaceutical composition of the third aspect.
In another preferred embodiment, the subject is a mammal, preferably a human.
It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments. Not to be reiterated herein, but to the extent of space.
Detailed Description
The present inventors have conducted extensive and intensive studies for a long time and have unexpectedly found a novel class of compounds which selectively inhibit SOS1 and/or exhibit improved pharmacodynamic properties. On this basis, the inventors have completed the present invention.
Term(s) for
In the present invention, unless otherwise specified, the terms used have the ordinary meanings well known to those skilled in the art.
The term "alkyl" refers to straight or branched chain or cyclic alkyl groups containing 1 to 20 carbon atoms, such as 1 to 18 carbon atoms, especially 1 to 18 carbon atoms. Typical "alkyl" groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, tert-butyl, and,Pentyl, isopentyl, heptyl, 4-dimethylpentyl, octyl, 2, 4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl and the like.
The term "C 1 -C 18 Alkyl "refers to straight or branched chain or cyclic alkyl groups including from 1 to 18 carbon atoms, such as methyl, ethyl, propyl, isopropyl (C) ((R))) N-butyl, t-butyl, isobutyl (e.g. butyl, isobutyl)) N-pentyl, isopentyl, n-hexyl, isohexyl, n-heptyl, isoheptyl. "substituted alkyl" means an alkyl group which is substituted at one or more positions, especially 1 to 4 substituents, and may be substituted at any position. Typical substitutions include, but are not limited to, one or more of the following groups: such as hydrogen, deuterium, halogen (e.g. mono-or polyhalo-substituents, the latter being e.g. trifluoromethyl or containing Cl 3 Alkyl group of (a), nitrile group, nitro group, oxygen (e.g., ═ O), trifluoromethyl group, trifluoromethoxy group, cycloalkyl group, alkenyl group, cycloalkenyl group, alkynyl group, heterocycle, aromatic ring, OR a 、SR a 、S(=O)R e 、S(=O) 2 R e 、P(=O) 2 R e 、S(=O) 2 OR e ,P(=O) 2 OR e 、NR b R c 、NR b S(=O) 2 R e 、NR b P(=O) 2 R e 、S(=O) 2 NR b R c 、P(=O) 2 NR b R c 、C(=O)OR d 、C(=O)R a 、C(=O)NR b R c 、OC(=O)R a 、OC(=O)NR b R c 、NR b C(=O)OR e ,NR d C(=O)NR b R c 、NR d S(=O) 2 NR b R c 、NR d P(=O) 2 NR b R c 、NR b C(=O)R a Or NR b P(=O) 2 R e Wherein R is present therein a May independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring, R b 、R c And R d May independently represent hydrogen, deuterium, alkyl, cycloalkyl, heterocycle or aromatic ring, or R b And R c Together with the N atom may form a heterocyclic ring; r e May independently represent hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring. Typical substituents as mentioned above, such as alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocyclic or aromatic ring, may be optionally substitutedAnd (4) generation.
The term "alkylene" refers to a group formed by removing a hydrogen atom from an "alkyl" group, such as methylene, ethylene, propylene, isopropylene (e.g.) Butylene (e.g. butyl oxide)Or) Pentylene (e.g. ethylene)) Hexamethylene (e.g. hexamethylene)) Heptylene (e.g. as) And the like.
The term "cycloalkyl" refers to a fully saturated cyclic hydrocarbon group comprising 1 to 4 rings containing 3 to 8 carbon atoms in each ring. "substituted cycloalkyl" means that one or more positions in the cycloalkyl group are substituted, especially 1 to 4 substituents, which may be substituted at any position. Typical substitutions include, but are not limited to, one or more of the following groups: such as hydrogen, deuterium, halogen (e.g. mono-or polyhalo-substituents, the latter being e.g. trifluoromethyl or containing Cl 3 Alkyl group of (a), nitrile group, nitro group, oxygen (e.g., ═ O), trifluoromethyl group, trifluoromethoxy group, cycloalkyl group, alkenyl group, cycloalkenyl group, alkynyl group, heterocycle, aromatic ring, OR a 、SR a 、S(=O)R e 、S(=O) 2 R e 、P(=O) 2 R e 、S(=O) 2 OR e ,P(=O) 2 OR e 、NR b R c 、NR b S(=O) 2 R e 、NR b P(=O) 2 R e 、S(=O) 2 NR b R c 、P(=O) 2 NR b R c 、C(=O)OR d 、C(=O)R a 、C(=O)NR b R c 、OC(=O)R a 、OC(=O)NR b R c 、NR b C(=O)OR e ,NR d C(=O)NR b R c 、NR d S(=O) 2 NR b R c 、NR d P(=O) 2 NR b R c 、NR b C(=O)R a Or NR b P(=O) 2 R e Wherein R is present therein a May independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring, R b 、R c And R d May independently represent hydrogen, deuterium, alkyl, cycloalkyl, heterocycle or aromatic ring, or R b And R c Together with the N atom may form a heterocyclic ring; r is e May independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring. The above typical substituents may be optionally substituted. Typical substitutions also include spirocyclic, bridged or fused ring substituents, especially spirocycloalkyl, spirocycloalkenyl, spiroheterocyclic (excluding heteroaromatic rings), bridged cycloalkyl, bridged alkenyl, bridged heterocyclic (excluding heteroaromatic rings), fused cycloalkyl, fused alkenyl, fused heterocyclyl or fused aromatic ring groups, which may be optionally substituted. Any two or more atoms on the ring may be further ring-connected with other cycloalkyl, heterocyclyl, aryl and heteroaryl groups.
The term "cycloalkylene" refers to a group formed by a cycloalkyl group minus two hydrogen atoms, such as: and the like.
The term "cycloalkylene" refers to a cycloalkylalkyl or alkylcycloalkyl group as defined above, wherein two hydrogen atoms have been removed, and wherein "C" is 1 -C 18 Alkylene radical C 3 -C 20 Cycloalkylene "or" C 3 -C 20 Cycloalkylene radical C 1 -C 18 Alkylene "has the same meaning, including but not limited to: etc., preferably, the alkylenecycloalkylene is C 1 -C 6 Alkylene radical C 3 -C 12 Cycloalkylene, more preferably C 1 -C 6 Alkylene radical C 3 -C 6 Cycloalkylene radicals.
The term "heterocyclyl" refers to a fully saturated or partially unsaturated cyclic group (including but not limited to, e.g., 3-7 membered monocyclic, 6-11 membered bicyclic, or 8-16 membered tricyclic ring systems) in which at least one heteroatom is present in the ring having at least one carbon atom. Each heteroatom-containing heterocyclic ring may carry 1,2,3 or 4 heteroatoms selected from nitrogen atoms, oxygen atoms or sulfur atoms, wherein the nitrogen or sulfur atoms may be oxidized and the nitrogen atoms may also be quaternized. The heterocyclic group may be attached to the residue of any heteroatom or carbon atom of the ring or ring system molecule. Exemplary monocyclic heterocycles include, but are not limited to, azetidinyl, pyrrolidinyl, oxetanyl, pyrazolinyl, imidazolinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuryl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, hexahydroazepinyl, 4-piperidinonyl, tetrahydropyranyl, morphinyl, thiomorpholinyl, thiomorpholino sulfoxide, thiomorpholino sulfone, 1, 3-dioxanyl, and tetrahydro-1, 1-dioxythiophene, and the like. Polycyclic heterocyclic groups include spiro, fused, and bridged heterocyclic groups; wherein the heterocyclic groups of the spiro, fused and bridged rings are optionally linked to other groups by single bonds, or are further linked to other cycloalkyl, heterocyclic, aryl and heteroaryl groups by any two or more atoms in the ring; the heterocyclic group may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, alkylthio, alkylamino, halogen, amino, nitro, hydroxy, mercapto, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylthio, oxo, carboxyl, and carboxylate groups, wherein any two or more atoms on the ring may be further ring-connected to other cycloalkyl, heterocyclyl, aryl, and heteroaryl groups.
The term "heterocyclylene" refers to a group formed by removing two hydrogen atoms from the above-mentioned heterocyclic group, and includes, but is not limited to: and the like.
The term "heterocycloalkylenealkylene" refers to a cycloalkylalkyl or alkylcycloalkyl group in which two hydrogen atoms have been removed, wherein "4-to 20-membered heterocycloalkylene C 1 -C 18 Alkylene "or" C 1 -C 18 Alkylene 4-20 membered heterocycloalkylene "has the same meaning, including but not limited to: etc., heterocycloalkylene is preferably 4-12 membered heterocycloalkylene C 1-6 Alkylene, more preferably 4-6 membered heterocycloalkylene C 1-6 An alkylene group.
The term "aryl" refers to an aromatic cyclic hydrocarbon group having 1 to 5 rings, in particularRefers to monocyclic and bicyclic groups such as phenyl, biphenyl, or naphthyl. Where the aromatic ring contains two or more aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group may be linked by a single bond (e.g., biphenyl), or fused (e.g., naphthalene, anthracene, etc.). "substituted aryl" means that one or more positions in the aryl group are substituted, especially 1 to 3 substituents, which may be substituted at any position. Typical substitutions include, but are not limited to, one or more of the following groups: such as hydrogen, deuterium, halogen (e.g. mono-or polyhalo-substituents, the latter being e.g. trifluoromethyl or containing Cl 3 Alkyl group of (a), nitrile group, nitro group, oxygen (e.g., ═ O), trifluoromethyl group, trifluoromethoxy group, cycloalkyl group, alkenyl group, cycloalkenyl group, alkynyl group, heterocycle, aromatic ring, OR a 、SR a 、S(=O)R e 、S(=O) 2 R e 、P(=O) 2 R e 、S(=O) 2 OR e ,P(=O) 2 OR e 、NR b R c 、NR b S(=O) 2 R e 、NR b P(=O) 2 R e 、S(=O) 2 NR b R c 、P(=O) 2 NR b R c 、C(=O)OR d 、C(=O)R a 、C(=O)NR b R c 、OC(=O)R a 、OC(=O)NR b R c 、NR b C(=O)OR e ,NR d C(=O)NR b R c 、NR d S(=O) 2 NR b R c 、NR d P(=O) 2 NR b R c 、NR b C(=O)R a Or NR b P(=O) 2 R e Wherein R is present therein a May independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring, R b 、R c And R d May independently represent hydrogen, deuterium, alkyl, cycloalkyl, heterocycle or aromatic ring, or R b And R c Together with the N atom may form a heterocyclic ring; r e May independently represent hydrogen, deuterium, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aromatic ring. The above typical substituents may be optionally substituted. Typical substitutions also include fused ring substituents, especially fusedCycloalkyl, fused ring alkenyl, fused ring heterocyclic group or fused ring aromatic ring group, the above cycloalkyl, cycloalkenyl, heterocyclic group and heterocyclic aryl group may be optionally substituted.
The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms, 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, nitrogen and sulfur. The heteroaryl group is preferably a 5-to 10-membered ring, more preferably a 5-or 6-membered ring, for example, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl, tetrazolyl and the like. "heteroaryl" may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, alkylthio, alkylamino, halogen, amino, nitro, hydroxy, mercapto, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylthio, oxo, carboxyl, and carboxylate.
The term "alkoxy" refers to a straight or branched chain or cyclic alkoxy group having 1 to 18 carbon atoms, including, without limitation, methoxy, ethoxy, propoxy, isopropoxy, butoxy, and the like. Preferably C 1 -C 8 Alkoxy, more preferably C 1 -C 6 An alkoxy group.
The term "oxo" refers to an ═ O group.
The term "alkyleneoxy" means "C 1 -C 18 An alkoxy group "one hydrogen atom off" is a group.
The term "halogen" or "halo" refers to chlorine, bromine, fluorine, iodine.
The term "halo" means substituted with halogen.
The term "deuterated" refers to a substitution by deuterium.
The term "hydroxyl" refers to a group with the structure OH.
The term "nitro" refers to a group with the structure NO 2 A group of (1).
The term "cyano" refers to a group with the structure CN.
The term "ester group" refers to a group with the structure-COOR, wherein R represents hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heterocycle or substituted heterocycle.
The term "amine" refers to a group having the structure-NRR ', where R and R' may independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heterocyclic or substituted heterocyclic, as defined above. R and R' may be the same or different in the dialkylamine fragment.
The term "amido" refers to a group with the structure-CONRR ', where R and R' may independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heterocycle or substituted heterocycle as defined above. R and R' may be the same or different in the dialkylamine fragment.
The term "sulfonamide" refers to a sulfonamide group having the structure-SO 2 NRR 'wherein R and R' may independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heterocyclic or substituted heterocyclic as hereinbefore defined. R and R' may be the same or different in the dialkylamine fragment.
The term "ureido" refers to a group having the structure — NRCONR 'R ", where R, R' and R" may independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heterocyclic or substituted heterocyclic, as defined above. R, R' and R "may be the same or different in the dialkylamine fragment.
The term "alkylaminoalkyl" refers to a group having the structure-RNHR ', wherein R and R' may independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heterocycle or substituted heterocycle as defined above. R and R' may be the same or different.
The term "dialkylaminoalkyl" refers to a group having the structure-RNHR 'R ", where R, R' and R" can independently represent alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, a heterocycle or a substituted heterocycle, as defined above. R, R' and R "may be the same or different in the dialkylamine fragment.
The term "heterocyclylalkyl" refers to a group having the structure-RR', wherein R may independently represent alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl; r' represents a heterocycle or a substituted heterocycle.
In the present invention, the term "substituted" means that one or more hydrogen atoms on a specified group are replaced with a specified substituent. Particular substituents are those described correspondingly in the foregoing, or as appearing in the examples. Unless otherwise specified, a substituted group may have a substituent selected from a specific group at any substitutable position of the group, and the substituent may be the same or different at each position. It will be understood by those skilled in the art that the combinations of substituents contemplated by the present invention are those that are stable or chemically achievable. Such substituents are for example (but not limited to): halogen, hydroxy, cyano, carboxy (-COOH), C 1 -C 6 Alkyl radical, C 2 -C 6 Alkenyl radical, C 2 -C 6 Alkynyl, C 3 -C 8 Cycloalkyl, 3-12 membered heterocyclyl, aryl, heteroaryl, C 1 -C 8 Aldehyde group, C 2 -C 10 Acyl radical, C 2 -C 10 Ester group, amino group, C 1 -C 6 Alkoxy radical, C 1 -C 10 Sulfonyl, and C 1 -C 6 Urea groups, and the like.
Unless otherwise stated, it is assumed that any heteroatom that is not in a valence state has sufficient hydrogen to replenish its valence state.
When the substituent is a non-terminal substituent, it is a subunit of the corresponding group, for example, alkyl corresponds to alkylene, cycloalkyl corresponds to cycloalkylene, heterocyclyl corresponds to heterocyclylene, alkoxy corresponds to alkyleneoxy, and the like.
Active ingredient
As used herein, "compounds of the invention" refers to compounds of formula I, and also includes stereoisomers or optical isomers, pharmaceutically acceptable salts, prodrugs or solvates of the compounds of formula I.
In the present invention, the compound represented by formula I has the following structure
Wherein, ring A, ring B, R, R' and R 1 、R 2 T and u are as defined above.
Preferably, at least one ring atom in ring a or ring B is N; more preferably, 1 to 5 (i.e., 1,2,3,4, 5) ring atoms in ring a or ring B are N; more preferably, ring a and ring B are each independently 6-membered heterocyclyl, 6-membered heteroaryl, phenyl.
Preferably, the compound has the structure shown in formula I
In the formula, R 1 、R 2 、X 1 、X 2 、X 3 、X 4 、X 5 、X 6 、X 7 、X 8 、X 9 Is as defined above.
Preferably, X 1 、X 2 、X 3 、X 4 、X 5 、X 6 、X 7 、X 8 And X 9 At least one of which is N.
Preferably, in the formulae I and I', R 2 Is methyl.
Preferably, the compound has the structure shown in formula (II):
in the formula, R 1 、X 1 、X 2 、X 3 、X 4 、X 5 、X 6 、X 7 、X 8 And X 9 Is as defined above.
Preferably, in each of the above formulae, R 1 Selected from the group consisting of substituted or unsubstituted: c 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl, phenyl, 5-10 membered heteroaryl; preferably, R 1 Selected from the group consisting of substituted or unsubstituted: phenyl, pyridyl, pyrimidinyl, indolyl, benzopyrazolyl, benzimidazolyl, benzothiazolyl,Wherein said substitution is by one or more groups selected from the group consisting of: hydrogen, deuterium, C 1 -C 6 Alkyl, deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea groups.
in the formula, R 3a -R 3f 、R 4a -R 4b 、R 5b -R 5c Is as defined above.
Preferably, in the present invention, R 3a -R 3f Each independently selected from the group consisting of substituted or unsubstituted: hydrogen, deuterium, C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl, C 3 -C 6 Cycloalkyl radical C 1 -C 6 Alkylene, 4-to 6-membered heterocycloalkyl C 1 -C 6 Alkylene, -O-C 1 -C 6 Alkyl, -O-C 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl-O-, C 3 -C 6 Cycloalkyl radical C 1 -C 6 alkylene-O-, 4-6 membered heterocycloalkyl C 1 -C 6 alkylene-O-, -O- (CH) 2 ) w C 1 -C 6 Alkoxy radical, R 12 -(C 3 -C 6 Cycloalkylene radical C 1 -C 6 Alkylene) -, R 12 - (4-to 6-membered heterocycloalkylene C) 1 -C 6 Alkylene) -, - (C) 3 -C 6 Cycloalkylene radical C 1 -C 6 Alkylene) -R 12 - (4-to 6-membered heterocycloalkylene C) 1 -C 6 Alkylene) -R 12 (ii) a Wherein w is 1,2,3 or 4;
R 12 selected from: hydrogen, deuterium, C 1 -C 6 Alkyl, deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy radical, C 3 -C 6 Cycloalkyloxy radical, C 6 -C 10 Aryl, 5-10 membered heteroaryl, 4-6 membered heterocyclyl, C 6 -C 10 Aryloxy, 5-10 membered heteroaryloxy, 4-6 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea;
R 4a -R 4b each independently selected from the group consisting of substituted or unsubstituted: hydrogen, C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl, C 3 -C 6 Cycloalkyl radical C 1 -C 6 Alkylene, 4-to 6-membered heterocycloalkyl C 1 -C 6 An alkylene group; wherein said substitution is by one or more groups selected from the group consisting of: deuterium, C 1 -C 6 Alkyl, deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy radical, R 12 -(C 3 -C 6 Cycloalkylene radical C 1 -C 6 Alkylene) -, R 12 - (4-to 6-membered heterocycloalkylene C) 1 -C 6 Alkylene) -, - (C) 3 -C 6 Cycloalkylene radical C 1 -C 6 Alkylene) -R 12 - (4-to 6-membered heterocycloalkylene C) 1 -C 6 Alkylene) -R 12 Halogen, oxo, nitro, hydroxyl, cyano, ester, amino, amido, sulfonamide, or ureido;
R 5b -R 5c each independently selected from the group consisting of substituted or unsubstituted: hydrogen, deuterium, C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl, C 3 -C 6 Cycloalkyl radical C 1 -C 6 Alkylene, 4-to 6-membered heterocycloalkyl C 1 -C 6 Alkylene, -O-C 1 -C 6 Alkyl, -O-C 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl-O-, C 3 -C 6 Cycloalkyl radical C 1 -C 6 alkylene-O-, 4-6 membered heterocycloalkyl C 1 -C 6 alkylene-O-, -O- (CH) 2 ) w C 1 -C 6 Alkoxy radical, R 12 -(C 3 -C 6 Cycloalkylene radical C 1 -C 6 Alkylene) -, R 12 - (4-to 6-membered heterocycloalkylene C) 1 -C 6 Alkylene) -, - (C) 3 -C 6 Cycloalkylene radical C 1 -C 6 Alkylene) -R 12 - (4-to 6-membered heterocycloalkylene C) 1 -C 6 Alkylene) -R 12 (ii) a Wherein w is 1,2,3 or 4;
wherein said substitution is by one or more groups selected from the group consisting of: deuterium, C 1 -C 6 Alkyl, aryl, heteroaryl, and heteroaryl,Deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea groups.
Preferably, in the present invention, R 3a -R 3f Each independently selected from the group consisting of substituted or unsubstituted: hydrogen, deuterium, C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl, C 3 -C 6 Cycloalkyl-methylene-, 4-6 membered heterocycloalkyl-methylene-, -O-C 1 -C 6 Alkyl, -O-C 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl-O-, C 3 -C 6 cycloalkyl-methylene-O-, 4-6 membered heterocycloalkyl-methylene-O-, -O- (CH) 2 ) w C 1 -C 6 Alkoxy radical, R 12 -(C 3 -C 6 Cycloalkylene-methylene) -, R 12 - (4-6 membered heterocycloalkylene-methylene) -, - (C) 3 -C 6 Cycloalkylene-methylene) -R 12 - (4-6 membered heterocycloalkylene-methylene) -R 12 (ii) a Wherein w is 1,2,3 or 4;
R 12 selected from: hydrogen, deuterium, C 1 -C 6 Alkyl, deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 3 -C 6 Cycloalkyl radical, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy radical, C 3 -C 6 Cycloalkyl oxy, C 6 -C 10 Aryl, 5-10 membered heteroaryl, 4-6 membered heterocyclyl, C 6 -C 10 Aryloxy, 5-10 membered heteroaryloxy, 4-6 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea;
R 4a -R 4b each independently selected from substituted or unsubstitutedSubstituted groups of the following group: hydrogen, C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl, C 3 -C 6 Cycloalkyl radical C 1 -C 6 Alkylene, 4-to 6-membered heterocycloalkyl C 1 -C 6 An alkylene group; wherein said substitution is by one or more groups selected from the group consisting of: deuterium, C 1 -C 6 Alkyl, deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy radical, R 12 -(C 3 -C 6 Cycloalkylene-methylene) -, R 12 - (4-6 membered heterocycloalkylene-methylene) -, - (C) 3 -C 6 Cycloalkylene-methylene) -R 12 - (4-to 6-membered heterocycloalkylene-methylene) -R 12 Halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea;
R 5b -R 5c each independently selected from the group consisting of substituted or unsubstituted: hydrogen, deuterium, C 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl, C 3 -C 6 Cycloalkyl-methylene-, 4-6 membered heterocycloalkyl-methylene-, -O-C 1 -C 6 Alkyl, -O-C 3 -C 6 Cycloalkyl, 4-6 membered heterocyclyl-O-, C 3 -C 6 cycloalkyl-methylene-O-, 4-6 membered heterocycloalkyl-methylene-O-, -O- (CH) 2 ) w C 1 -C 6 Alkoxy radical, R 12 -(C 3 -C 6 Cycloalkylene-methylene) -, R 12 - (4-6 membered heterocycloalkylene-methylene) -, - (C) 3 -C 6 Cycloalkylene-methylene) -R 12 - (4-to 6-membered heterocycloalkylene-methylene) -R 12 (ii) a Wherein w is 1,2,3 or 4;
wherein said substitution is by one or more groups selected from the group consisting of: deuterium, C 1 -C 6 Alkyl, deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea groups.
Preferably, unless otherwise specified, said substitution means substitution by one or more groups selected from the group consisting of: hydrogen, deuterium, C 1 -C 6 Alkyl, deuterated C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl, halo C 1 -C 6 Alkyl hydroxy, C 3 -C 6 Cycloalkyl radical, C 1 -C 6 Alkoxy, deuterated C 1 -C 6 Alkoxy, halo C 1 -C 6 Alkoxy radical, C 3 -C 6 Cycloalkyl oxy, C 6 -C 10 Aryl, 5-10 membered heteroaryl, 4-6 membered heterocyclyl, C 6 -C 10 Aryloxy, 5-10 membered heteroaryloxy, 4-6 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea.
The salts which the compounds of the invention may form are also within the scope of the invention. Unless otherwise indicated, the compounds of the present invention are understood to include their salts. The term "salt" as used herein refers to a salt formed from an inorganic or organic acid and a base in either an acidic or basic form. Furthermore, when a compound of the present invention contains a basic moiety, including but not limited to pyridine or imidazole, and an acidic moiety, including but not limited to carboxylic acid, zwitterions ("inner salts") that may form are included within the scope of the term "salt(s)". Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are useful, e.g., in isolation or purification steps of the preparation. The compounds of the invention may form salts, for example, by reacting compound I with an amount of acid or base, e.g. an equivalent amount, and then precipitating out in a medium, or by lyophilization in aqueous solution.
The compounds of the invention may contain basic moieties, including but not limited to amine or pyridine or imidazole rings, which may form salts with organic or inorganic acids. Typical acids which may form salts include acetates (e.g. with acetic acid or trihaloacetic acid such as trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, diglycolates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptonates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides, hydrobromides, hydroiodides, hydroxyethanesulfonates (e.g. 2-hydroxyethanesulfonates), lactates, maleates, methanesulfonates, naphthalenesulfonates (e.g. 2-naphthalenesulfonates), nicotinates, nitrates, oxalates, pectinates, persulfates, phenylpropionates (e.g. 3-phenylpropionates), phosphates, propionates, citrates, and the like, Picrates, pivalates, propionates, salicylates, succinates, sulfates (e.g., with sulfuric acid), sulfonates, tartrates, thiocyanates, tosylates, e.g., p-toluenesulfonate, dodecanoate, and the like
Certain compounds of the present invention may contain acidic moieties, including but not limited to carboxylic acids, which may form salts with various organic or inorganic bases. Typical salts with bases include ammonium salts, alkali metal salts such as sodium, lithium, potassium salts, alkaline earth metal salts such as calcium, magnesium salts, and salts with organic bases (e.g., organic amines) such as benzathine, dicyclohexylamine, hydrabamine (salt with N, N-bis (dehydroabietyl) ethylenediamine), N-methyl-D-glucamine, N-methyl-D-glucamide, t-butylamine, and salts with amino acids such as arginine, lysine, and the like. The basic nitrogen-containing groups may be combined with halide quaternary ammonium salts, such as small molecule alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, dodecyl, tetradecyl, and tetradecyl chlorides, bromides, and iodides), aralkyl halides (e.g., benzyl and phenyl bromides), and the like.
Prodrugs and solvates of the compounds of the invention are also contemplated. The term "prodrug" as used herein refers to a compound that undergoes chemical conversion by metabolic or chemical processes to yield a compound, salt, or solvate of the present invention when used in the treatment of a related disease. The compounds of the present invention include solvates, such as hydrates.
The compounds, salts or solvates of the invention, in tautomeric forms (for example amides and imine ethers) may be present. All of these tautomers are part of the present invention.
All stereoisomers of the compounds (e.g., those asymmetric carbon atoms that may exist due to various substitutions), including enantiomeric and diastereomeric forms thereof, are contemplated within the invention. The individual stereoisomers of the compounds of the invention may not be present in combination with the other isomers (e.g. as a pure or substantially pure optical isomer having a particular activity), or may be present as a mixture, e.g. as a racemate, or as a mixture with all or a portion of the other stereoisomers. The chiral center of the invention has two S or R configurations, and is defined by the International Union of theory and applied chemistry (IUPAC) proposed in 1974. Racemic forms can be resolved by physical methods such as fractional crystallization, or by separation of the crystals by derivatization into diastereomers, or by chiral column chromatography. The individual optical isomers can be obtained from the racemates by any suitable method, including, but not limited to, conventional methods such as salt formation with an optically active acid followed by crystallization.
The compounds of the present invention, obtained by preparing, isolating and purifying the compound in sequence, have a weight content of 90% or more, for example, 95% or more, 99% or more ("very pure" compounds), as set forth in the text. Such "very pure" compounds of the invention are also part of the invention herein.
All configurational isomers of the compounds of the invention are within the scope of the invention, whether in mixture, pure or very pure form. The definition of the compounds of the present invention includes both cis (Z) and trans (E) alkene isomers, as well as cis and trans isomers of carbocyclic and heterocyclic rings.
Throughout the specification, groups and substituents may be selected to provide stable fragments and compounds.
Specific functional groups and definitions of chemical terms are detailed below. For purposes of the present invention, the chemical Elements are compatible with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics,75 th D. as defined in. The definition of a particular functional group is also described herein. In addition, the basic principles of Organic Chemistry, as well as specific functional groups and reactivities are also described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausaltito: 1999, which is incorporated by reference in its entirety.
Certain compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention encompasses all compounds, including cis and trans isomers, R and S enantiomers, diastereomers, (D) isomer, (L) isomer, racemic mixtures and other mixtures thereof. Further the asymmetric carbon atom may represent a substituent such as an alkyl group. All isomers, as well as mixtures thereof, are encompassed by the present invention.
According to the present invention, the mixture of isomers may contain a variety of isomer ratios. For example, in a mixture of only two isomers there may be the following combinations: 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0, all ratios of isomers are within the scope of the invention. Similar ratios, as well as ratios that are mixtures of more complex isomers, are readily understood by those of ordinary skill in the art to be within the scope of this invention.
The invention also includes isotopically-labeled compounds, equivalent to those disclosed herein as the original compound. It will generally occur that in practice one or more atoms are replaced by an atom having a different atomic mass or mass number from the atomic mass or mass number. Examples of isotopes that can be listed as compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, respectively 2 H、 3 H、 13 C、 11 C、 14 C、 15 N、 18 O、 17 O、 31 P、 32 P、 35 S、 18 F and 36 and (4) Cl. The compounds of the present invention, or enantiomers, diastereomers, isomers, or pharmaceutically acceptable salts or solvates thereof, wherein isotopes or other isotopic atoms containing those compounds are within the scope of the present invention. Certain isotopically-labelled compounds of the invention, e.g. 3 H and 14 among these, the radioactive isotope of C is useful in tissue distribution experiments of drugs and substrates. Tritium, i.e. 3 H and carbon-14, i.e. 14 C, their preparation and detection are relatively easy. Is the first choice among isotopes. Furthermore, heavier isotopes such as deuterium are substituted, i.e. 2 H, due to its good metabolic stability, may be advantageous in certain therapies, such as increased half-life in vivo or reduced dose, and therefore, may be preferred in certain circumstances. Isotopically labeled compounds can be prepared by conventional methods by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent using the protocols disclosed in the examples.
If it is desired to design the synthesis of a particular enantiomer of a compound of the invention, it may be prepared by asymmetric synthesis or derivatised with chiral auxiliary agents, the resulting diastereomeric mixtures separated and the chiral auxiliary removed to give the pure enantiomers. Alternatively, if the molecule contains a basic functional group, such as an amino acid, or an acidic functional group, such as a carboxyl group, diastereomeric salts can be formed therewith with an appropriate optically active acid or base, and the isolated enantiomers can be obtained in pure form by conventional means such as fractional crystallization or chromatography.
As described herein, the compounds of the present invention can be substituted with any number of substituents or functional groups to extend their inclusion range. In general, the term "substituted", whether occurring before or after the term "optional", in the formula of the present invention including substituents, means that the hydrogen radical is replaced with a substituent of the indicated structure. When a plurality of the specified structures are substituted at a position with a plurality of the specified substituents, each position of the substituents may be the same or different. The term "substituted" as used herein includes all permissible substitutions of organic compounds. In a broad sense, permissible substituents include acyclic, cyclic, branched unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic organic compounds. In the present invention, the heteroatom nitrogen may have a hydrogen substituent or any permissible organic compound described hereinabove to supplement its valence state. Furthermore, the present invention is not intended to be limited in any way as to the permissible substitution of organic compounds. The present invention recognizes that the combination of substituents and variable groups is excellent in the treatment of diseases, such as infectious diseases or proliferative diseases, in the form of stable compounds. The term "stable" as used herein refers to compounds that are stable enough to maintain the structural integrity of the compound when tested for a sufficient period of time, and preferably are effective for a sufficient period of time, and are used herein for the purposes described above.
Metabolites of the compounds referred to herein and pharmaceutically acceptable salts thereof, as well as prodrugs that are convertible in vivo into the structures of the compounds referred to herein and pharmaceutically acceptable salts thereof, are also encompassed by the claims herein.
Preparation method
The process for preparing the compounds of formula (I) according to the invention is described in more detail below, but these particular processes do not limit the invention in any way. The compounds of the present invention may also be conveniently prepared by optionally combining various synthetic methods described in the present specification or known in the art, and such combinations may be readily carried out by those skilled in the art to which the present invention pertains.
Typically, the process for the preparation of the compounds of the present invention is as follows, wherein the starting materials and reagents used are commercially available without specific reference.
Preferably, the compounds of the present invention are prepared by the following method
(i) In an inert solvent, a base (e.g. TEA, DIPEA, DMAP or K) 2 CO 3 ) Reacting the compound of formula V-1 with the compound of formula V-2 in the presence of a condensing agent (such as BOP, PyBOP, HATU or DCC) or a Pd catalyst to obtain the compound of formula (I);
in the formula (I), the compound is shown in the specification,
x is selected from: halogen, OH, O, OTf, OTs, Oms, etc.;
R 1 、R 2 r, R', ring A, ring B, u and t are as defined above.
Preferably, the compounds of the present invention are prepared by the following method
(i ') A compound of formula V' -1 in a base (e.g. TEA, DIPEA, DMAP or K) 2 CO 3 ) Reacting with the compound of formula V '-2 under the action of a condensing agent (such as BOP, PyBOP, HATU or DCC) or Pd catalyst to obtain the compound of formula (I');
in the formula (I), the compound is shown in the specification,
x is selected from: halogen, OH, O, OTf, OTs, Oms, etc.;
Pharmaceutical compositions and methods of administration
The pharmaceutical composition is used for preventing and/or treating the following diseases: inflammation, cancer, cardiovascular disease, infection, immunological disease, and metabolic disease.
The compounds of general formula (I) may be used in combination with other drugs known to treat or ameliorate similar conditions. When administered in combination, the mode of administration and dosage of the original drug may be maintained unchanged while the compound of formula I is administered simultaneously or subsequently. When the compound of the formula I is administered simultaneously with one or more other drugs, a pharmaceutical composition containing one or more known drugs together with the compound of the formula I can be preferably used. The pharmaceutical combination also includes administration of the compound of formula I in an overlapping time period with one or more other known drugs. When a compound of formula I is administered in a pharmaceutical combination with one or more other drugs, the dose of the compound of formula I or the known drug may be lower than the dose at which they are administered alone.
Drugs or active ingredients that may be used in combination with the compounds of formula (I) include, but are not limited to: PD-1 inhibitors (e.g., nivolumab, pembrolizumab, pidilizumab, cemipimab, JS-001, SHR-120, BGB-A317, IBI-308, GLS-010, GB-226, STW204, HX008, HLX10, BAT 1306, AK105, LZM 009, or biologically similar drugs thereof), PD-L1 inhibitors (e.g., durvalumab, atezolimab, avelumab, CS1001, KN035, HLX20, SHR-1316, BGB-A333, JS003, CS1003, A167, F520, GR1405, MSB2311, or biologically similar drugs thereof), CD20 antibodies (e.g., rituximab, OBINzumamab, OFatumumab, IBtuzumab, tosummamab, TOSITUMOMAb, I131-itimumab, Hulmumab 90, ALOMIfK-90, ALOMIfI-35, SANtX 3978, ALOMIfI-35, SANtX-150, ESK-35, ESK-S-K-35, ESK-K-II, ESK-II, ESK-III, ESK-II, ESK-III, ESSES-III, ESK-III, ESP, ESSES-III, ESP-II, ESP-III, ESP-II, ESP, ESB, ES, Alectonib, Brigatinib, Lorlatinib, oxcarinib), PI3K inhibitors (e.g., Idelalisib, Duvelisib, Dactolisib, Taselisib, Bimiralisib, Omipaliib, Buparlisib, etc.), BTK inhibitors (e.g., Ibrutinib, Tirabutinib, Acalabastib, Zanbutrutinib, Vecabutinib, etc.), EGFR inhibitors (e.g., Afatinib, Gefitinib, Erlottinib, Lapatinib, Dacomitib, Icotinib, Canertinib, Sapinotinib, Naquratinib, Pyrotinib, Rocilitiniib, Osimetiniib, etc.), inhibitors (e.g., Sorafenib, Parraertinib, Lorlatinib 6284, Lipocinib, etc.), inhibitors (e.g., Lipocinib, VEGF-12, Lipocinib, VEGF-III inhibitors, Lipocinib, VEGF-12, Lipocinib, VEGF-III inhibitors, Lipocinib inhibitors (e, Lipocinib inhibitors, etc.), inhibitors, VEGF-12, Lipocinib inhibitors, VEGF-12, Lipocinib inhibitors, VEGF-III inhibitors, VEGF-12, Lipocinib inhibitors, VEGF-III inhibitors, Lipocinib inhibitors, VEGF-12, Lipocinib inhibitors, VEGF-III inhibitors, Lipocinib inhibitors, VEGF-12, VEGF-III inhibitors, VEGF-12, VEGF-III inhibitors, VEGF-12, Lipocinib inhibitors, VEGF-III inhibitors, etc.), etc. (e, VEGF-III inhibitors, etc.), and so AS inhibitors, VEGF-12, VEGF-inhibitors (e, VEGF-inhibitors, Lipocinib inhibitors, VEGF-12, Lipocinib inhibitors, VEGF-inhibitors, Lipocinib inhibitors, VEGF-12, Lipocinib inhibitors, VEGF-inhibitors, Lipocinib inhibitors, VEGF-inhibitors, Lipocinib inhibitors, VEGF-12, Lipocinib inhibitors, such AS inhibitors, Lipocinib inhibitors, VEGF-12, VEGF-inhibitors, Lipocinib inhibitors, VEGF-inhibitors, e, VEGF-12, Lipocinib inhibitors, e, VEGF-inhibitors, Lipocinib inhibitors, VEGF-inhibitors, Lipocinib inhibitors, VEGF-inhibitors, e, Lipocinib inhibitors, Lip.
Dosage forms of the pharmaceutical compositions of the present invention include (but are not limited to): injection, tablet, capsule, aerosol, suppository, pellicle, dripping pill, topical liniment, controlled release type or delayed release type or nanometer preparation.
The pharmaceutical composition of the present invention comprises the compound of the present invention or a pharmacologically acceptable salt thereof and a pharmacologically acceptable excipient or carrier in a safe and effective amount range. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1-2000mg of a compound of the invention per dose, more preferably, 10-1000mg of a compound of the invention per dose. Preferably, said "dose" is a capsule or tablet.
"pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances which are suitable for human use and must be of sufficient purity and sufficiently low toxicity. By "compatible" is meant herein that the components of the composition are capable of intermixing with and between the compounds of the present invention without significantly diminishing the pharmaceutical effectiveness of the compounds. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g. sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g. stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g. soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g. propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (e.g. tween, etc.)) Wetting agents (e.g., sodium lauryl sulfate), coloring agents, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, and the like.
The mode of administration of the compounds or pharmaceutical compositions of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, for example, hydroxymethyl cellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrating agents, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) absorption accelerators, e.g., quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glycerol monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents.
Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shells such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such compositions may be delayed in release in a certain part of the digestive tract. Examples of embedding components which can be used are polymeric substances and wax-like substances. If desired, the active compound may also be in microencapsulated form with one or more of the above-mentioned excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly employed in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, in particular, cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of such materials and the like.
In addition to these inert diluents, the compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols and suitable mixtures thereof.
Dosage forms for topical administration of the compounds of the present invention include ointments, powders, patches, sprays, and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants which may be required if desired.
The therapeutic methods of the invention can be administered alone or in combination with other therapeutic means or agents.
When the pharmaceutical composition is used, a safe and effective amount of the compound of the present invention is suitable for mammals (such as human beings) to be treated, wherein the administration dose is a pharmaceutically-considered effective administration dose, and for a human body with a weight of 60kg, the daily administration dose is usually 1 to 2000mg, preferably 50 to 1000 mg. Of course, the particular dosage will also take into account such factors as the route of administration, the health of the patient, and the like, which are within the skill of the skilled practitioner.
The invention also provides a preparation method of the pharmaceutical composition, which comprises the following steps: mixing a pharmaceutically acceptable carrier with the compound of the general formula (I) or a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof to form the pharmaceutical composition.
The present invention also provides a method of treatment comprising the steps of: administering a compound of formula (I), or a crystalline form, a pharmaceutically acceptable salt, hydrate, or solvate thereof, as described herein, or a pharmaceutical composition as described herein, to a subject in need of such treatment, for selectively inhibiting SOS 1.
Compared with the prior art, the invention has the following main advantages:
(1) the compound has good selective inhibition effect on SOS 1;
(2) the compound has better in vivo and in vitro pharmacodynamics and pharmacokinetic performance and lower toxic and side effects.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Experimental procedures without specific conditions noted in the following examples, molecular cloning is generally performed according to conventional conditions such as Sambrook et al: the conditions described in the Laboratory Manual (New York: Cold Spring Harbor Laboratory Press,1989), or according to the manufacturer's recommendations. Unless otherwise indicated, percentages and parts are by weight.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials described herein are intended to be exemplary only.
The structure of the compounds of the invention is determined by Nuclear Magnetic Resonance (NMR) and liquid mass chromatography (LC-MS).
NMR was detected using a Bruker AVANCE-400 nuclear magnetic spectrometer, and the assay solvent contained deuterated dimethyl sulfoxide (DMSO-d) 6 ) Deuterated acetone (CD) 3 COCD 3 ) Deuterated chloroform (CDCl) 3 ) And deuterated methanol (CD) 3 OD), and internal standards are Tetramethylsilane (TMS), chemical shifts are measured in parts per million (ppm).
Liquid chromatography-mass spectrometry (LC-MS) was detected using a Waters SQD2 mass spectrometer. HPLC measurements were performed using an Agilent1100 high pressure chromatograph (Microsorb 5micron C18100 x 3.0.0 mm column).
Thin layer chromatography silica gel plate is blue island GF254 silica gel plate, TLC adopts 0.15-0.20mm, and preparative thin layer chromatography adopts 0.4-0.5 mm. Column chromatography generally uses Qingdao silica gel 200-300 mesh silica gel as a carrier.
The starting materials in the examples of the present invention are known and commercially available or may be used or synthesized according to literature reports in the art.
All reactions of the present invention are carried out under continuous magnetic stirring in a dry inert gas (e.g., nitrogen or argon) at temperatures in degrees celsius, unless otherwise specified.
Examples
Example 1 preparation of (R) -5- ((1- (3-amino-5- (trifluoromethyl) phenyl) ethyl) amino) -3-cyclopropyl-1, 7-dimethylpyrimidine [4,5-d ] pyrimidine-2, 4(1H,3H) -dione
The first step is as follows: (E) preparation of (E) -N, N-dimethyl-N' - (3-methyl-2, 6-dioxo-1, 2,3, 6-tetrahydropyrimidin-4-yl) carboximide
To a solution of 6-amino-1-methylpyrimidine-2, 4(1H,3H) -dione (10.0g,70.8mmol,1.00eq) in DMF (50mL) was added DMF-DMA (16.8g,141mmol,18.8mL,2.00 eq). The reaction was stirred at 40 ℃ for 4h and then cooled to 0 ℃. The resulting mixture was filtered, and the filter cake was washed with MTBE (50mL) and dried to give the desired product (14.0g,64.2mmol, 90.6% yield).
LC-MS:m/z 197(M+H) + 。
The second step is that: (E) preparation of (E) -N' - (1-cyclopropyl-3-methyl-2, 6-dioxo-1, 2,3, 6-tetrahydropyrimidin-4-yl) -N, N-dimethylformimide
(E) Na was added to a solution of (E) -N, N-dimethyl-N' - (3-methyl-2, 6-dioxo-1, 2,3, 6-tetrahydropyrimidin-4-yl) carboximide (15.0g,76.4mmol,1.00eq) and cyclopropylboronic acid (7.88g,91.7mmol,1.20eq) in dimethyl carbonate (150mL) 2 CO 3 (16.2g,152mmol,2.00eq)、Cu(OAc) 2 (2.78g15.3mmol,0.20eq) and 2- (2-pyridyl) pyridine (2.39g,15.3mmol,0.20 eq). The reaction was stirred at 75 ℃ for 16h and then cooled to room temperature. The resulting mixture was filtered through celite and the filter cake was washed with EtOAc (100 mL). Saturated NH for filtrate 4 The Cl aqueous solution was washed (300mL), the aqueous phase was separated and extracted with EtOAc (3 x 500 mL). The combined organic phases were washed with saturated brine, dried and concentrated under reduced pressure. The residue was slurried with MTBE (150mL) to give the desired product (11.0g,46.5mmol, 60.9% yield).
LC-MS:m/z 237(M+H) + 。
The third step is the preparation of 6-amino-3-cyclopropyl-1-methylpyrimidine-2, 4(1H,3H) -dione
(E) To a solution of (E) -N' - (1-cyclopropyl-3-methyl-2, 6-dioxo-1, 2,3, 6-tetrahydropyrimidin-4-yl) -N, N-dimethylformimide (6.00g,25.4mmol,1.00eq) in MeOH (40mL) was added NaOH (2M,25.4mL,2.00 eq). The reaction was stirred at 25 ℃ for 2h, then concentrated under reduced pressure to remove methanol. The residue was filtered and the filter cake was collected and dried to give the desired product (2.80g,14.7mmol, 57.8% yield).
LC-MS:m/z 182(M+H) + 。
The fourth step is the preparation of ethyl 6-amino-3-cyclopropyl-1-methyl-2, 4-dioxo-1, 2,3, 4-tetrahydropyrimidine-5-carboxylate
To a solution of 6-amino-3-cyclopropyl-1-methylpyrimidine-2, 4(1H,3H) -dione (4.50g,24.8mmol,1.00eq) in Py (88.2g,1.12mol,90.0mL,44.9eq) was added ethyl chloroformate (23.3g,214mmol,20.5mL,8.66eq) dropwise at 0 ℃. After the dropwise addition, the reaction mixture was stirred at 90 ℃ for 12h, then cooled to room temperature and then quenched with saturated NH at 0 ℃ 4 Cl (200mL) was quenched, followed by extraction with DCM (300mL x 3). The combined organic phases were washed with saturated brine, dried and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography to give the objective product (3.5g,12.4mmol, 50.1% yield).
LC-MS:m/z 254(M+H) + 。
The fifth step is the preparation of 6-amino-3-cyclopropyl-1-methyl-dioxo-1, 2,3, 4-tetrahydropyrimidine-5-carboxamide
6-amino-3-cyclopropyl-1-methyl-2, 4-dioxo-1, 2,3, 4-tetrahydropyrimidine-5-carboxylic acid ethyl ester (1.70g,6.71mmol,1.00eq) in DMF (10mL) solutionAdding NH 3 .H 2 O (30.9g,265mmol,34.0mL, 30.0% purit, 39.5 eq). The reaction mixture was stirred at 130 ℃ for 16 hours in a sealed state, and then concentrated under reduced pressure. The residue was slurried with water to give the desired product (1.20g,5.08mmol, 75.7% yield).
LC-MS:m/z 225(M+H) + 。
The sixth step is the preparation of 3-cyclopropyl-1, 7-dimethylpyrimidine [4,5-d ] pyrimidine-2, 4,5(1H,3H,6H) -trione
Ac of 6-amino-3-cyclopropyl-1-methyl-dioxo-1, 2,3, 4-tetrahydropyrimidine-5-carboxamide (600mg,2.68mmol,1.00eq) 2 A solution of O (2.18g,21.3mmol,2.00mL,7.9. eq.) was stirred at 140 ℃ for 3h, then concentrated under reduced pressure. The residue was slurried with water to give the desired product (0.42g,1.61mmol, 60.1% yield).
LC-MS:m/z 249(M+H) + 。
The seventh step is the preparation of (R) -5- ((1- (3-amino-5- (trifluoromethyl) phenyl) ethyl) amino) -3-cyclopropyl-1, 7-dimethylpyrimidine [4,5-d ] pyrimidine-2, 4(1H,3H) -dione
3-cyclopropyl-1, 7-dimethylpyrimidine [4,5-d]To a solution of pyrimidine-2, 4,5(1H,3H,6H) -trione (0.20g,805umol,1.00eq) in DMF (2mL) was added PyBOP (838mg,1.61mmol,2.00eq) and TEA (407mg,4.03mmol,5601uL,5.00 eq). The reaction was stirred at room temperature for 30min, followed by addition of (R) -3- (1-aminoethyl) -5- (trifluoromethyl) aniline (246mg,1.21mmol,4.98uL,1.50 eq). The resulting reaction was stirred at room temperature for 30min, followed by EtOAc (20mL) and H 2 Layers were separated between O (5 mL). The combined organic phases were washed with saturated brine, dried and concentrated under reduced pressure. The residue was separated by preparative chromatography to give the desired product (0.18g,414umol, 51.4% yield, 98.9% purity).
LC-MS:m/z 435(M+H) + 。 1 HNMR:(400MHz,DMSO-d6)δ9.29(d,J=8.28Hz,1H)6.82(s,2H)6.74(s,1H)5.62(s,2H)5.37(quin,J=7.15Hz,1H)3.40(s,3H)2.58-2.65(m,1H)2.39(s,3H)1.51(d,J=7.03Hz,3H)0.96-1.06(m,2H)0.69-0.79(m,2H)。
Example 2 preparation of (R) -5- ((1- (3-amino-5- (trifluoromethyl) phenyl) ethyl) amino) -1-cyclopropyl-3, 7-dimethylpyrimidine [4,5-d ] pyrimidine-2, 4(1H,3H) -dione
The first step is as follows: preparation of 1-cyclopropyl-3-methylurea
Cyclopropylamine (8.00g,140mmol,9.71mL,1.00eq) and Et 3 A solution of N (28.3g,280mmol,39.0mL,2.00eq) in DCM (100mL) was cooled to 0 deg.C, followed by dropwise addition of N-methyl-chloroformamide (13.1g,140mmol,1.00 eq). The reaction solution was reacted at 25 ℃ for 2 hours and then filtered. The filtrate was collected and concentrated under reduced pressure to give the desired product (16.0g,112mmol, 80.0% yield). The product is used for the next reaction without purification.
LC-MS:m/z 115(M+H) + 。
The second step is that: preparation of 2-cyano-N- (cyclopropylcarbamoyl) -N-methylacetamide
Under a nitrogen atmosphere, a solution of 1-cyclopropyl-3-methylurea (16.0g,140mmol,1.00eq) and cyanoacetic acid (23.8g,280mmol,2.00eq) in DMF (120mL) was added with Ms 2 O (29.3g,168mmol,1.20 eq). The reaction solution is reacted for 4H at 25 ℃ and then is reacted with H 2 O (200mL) diluted and extracted with EtOAc (100mL x 3). The combined organic phases were washed with saturated brine, dried and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography to obtain the objective product (18.0g,89.4mmol, 63.8% yield).
LC-MS:m/z 182(M+H) + 。
The third step: preparation of 6-amino-1-cyclopropyl-3-methylpyrimidine-2, 4(1H,3H) -dione
2-cyano-N- (cyclopropylcarbamoyl) -N-methylacetamide (16.0g,88.3mmol,1.00eq) and NaOH (706mg,17.7mmol,0.20eq) in H 2 O (220mL) solution was reacted at 80 ℃ for 1h, then cooled to room temperature and stirred at room temperature for 2-3 h. The resulting mixture was filtered, and the filter cake was washed with water and collected and dried to give the desired product (11.5g,60.3mmol, 68.3% yield).
LC-MS:m/z 182(M+H) + 。
The fourth step: preparation of 6-amino-1-cyclopropyl-3-methyl-2, 4-dioxo-1, 2,3, 4-tetrahydropyrimidine-5-carboxylic acid ethyl ester
At 0 ℃, 6-amino-1-Ethyl chloroformate (24.8g,229mmol,21.8mL,5.94eq) was added dropwise to a solution of cyclopropyl-3-methylpyrimidine-2, 4(1H,3H) -dione (7.00g,38.6mmol,1.00eq) in Py (137g,1.73mol,140mL,44.9 eq). After the dropwise addition, the reaction solution was stirred at 90 ℃ for 12 hours, then cooled to room temperature, and then saturated NH was added at 0 ℃ 4 Cl (200mL) was quenched and then extracted with DCM (300mL × 3). The combined organic phases were washed with saturated brine, dried and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography to give the objective product (2.60g,9.75mmol, 25.2% yield).
LC-MS:m/z 254(M+H) + 。
The fifth step: preparation of 6-amino-1-cyclopropyl-3-methyl-2, 4-dioxo-1, 2,3, 4-tetrahydropyrimidine-5-carboxamide
To a solution of ethyl 6-amino-1-cyclopropyl-3-methyl-2, 4-dioxo-1, 2,3, 4-tetrahydropyrimidine-5-carboxylate (0.80g,3.16mmol,1.00eq) in DMF (10mL) was added NH 3 .H 2 O (14.5g,124mmol,16.0mL, 30.0% purit, 39.5 eq). The reaction solution was stirred at 130 ℃ for 16 hours in a sealed state and then concentrated under reduced pressure. The residue was slurried with water to give the title product (0.42g,1.69mmol, 53.4% yield).
LC-MS:m/z 225(M+H) + 。
And a sixth step: preparation of 1-cyclopropyl-3, 7-dimethylpyrimidine [4,5-d ] pyrimidine-2, 4,5(1H,3H,6H) -trione
Ac of 6-amino-1-cyclopropyl-3-methyl-2, 4-dioxo-1, 2,3, 4-tetrahydropyrimidine-5-carboxamide (0.40g,1.78mmol,1.00eq) 2 A solution of O (2.18g,21.3mmol,2.00mL,11.9eq) was stirred at 140 ℃ for 16h, then concentrated under reduced pressure, and the residue was slurried with water to give the title product (0.20g,765umol, 42.9% yield).
LC-MS:m/z 249(M+H) + 。
The seventh step: preparation of (R) -5- ((1- (3-amino-5- (trifluoromethyl) phenyl) ethyl) amino) -1-cyclopropyl-3, 7-dimethylpyrimidine [4,5-d ] pyrimidine-2, 4(1H,3H) -dione
1-cyclopropyl-3, 7-dimethylpyrimidine [4,5-d ]]To a solution of pyrimidine-2, 4,5(1H,3H,6H) -trione (0.14g,564umol,1.00eq) in DMF (2mL) was added PyBOP (584mg,1.13mmol,2.00eq) and TEA (285mg,2.82mmol,392uL,5.00 eq). The reaction was stirred at room temperature for 30min, followed by addition of (R) -3- (1-Aminoethyl) -5- (trifluoromethyl) aniline (173mg,846umol,4.98uL,1.50 eq). The resulting reaction was stirred at room temperature for 30min, followed by EtOAc (20mL) and H 2 Layers were separated between O (5 mL). The combined organic phases were washed with saturated brine, dried and concentrated under reduced pressure. The residue was separated by preparative chromatography to give the desired product (80.6mg,179umol, 31.9% yield).
LC-MS:m/z 435(M+H) + 。 1 HNMR:(400MHz,DMSO-d6)δ9.25(d,J=8.19Hz,1H)6.81(s,2H)6.74(s,1H)5.61(s,2H)5.28-5.41(m,1H)3.22(s,3H)2.72-2.83(m,1H)2.41(s,3H)1.50(d,J=6.85Hz,3H)1.01-1.15(m,2H)0.69-0.87(m,2H)。
EXAMPLE 34 preparation of- (((R) -1- (3-amino-5- (trifluoromethyl) phenyl) ethyl) amino) -2, 8-dimethyl-6- (((S) -tetrahydrofuran-3-yl) oxy) pyridin [2,3-d ] pyrimidin-7 (8H) -one
The first step is as follows: preparation of methyl 2-chloro-1-methyl-6-oxo-1, 6-dihydropyridine-3-carboxylate
LiH (0.900g,129mmol,1.10mL,2.50eq) was added to a solution of 2-chloro-1-methyl-6-oxo-1, 6-dihydropyridine-3-carboxylic acid (9.00g,51.9mmol,1.00eq) in DMF (150mL) at 0 ℃. The reaction solution is reacted for 0.5h at 0 ℃, and then CH is added 3 I (16.2g,114mmol,7.10mL,2.20 eq). The resulting mixture was stirred at 25 ℃ for 1.5h, then quenched with 2M HCl (50mL) at 0 ℃. The resulting mixture was diluted with water (200mL) and extracted with EtOAc (400 mL). The combined organic phases were washed with saturated brine, dried and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography to isolate the objective product (7.00g,34.7mmol, 67.0% yield).
LC-MS:m/z 202(M+H) + 。
The second step is that: preparation of 4-hydroxy-2, 8-dimethylpyridin [2,3-d ] pyrimidin-7 (8H) -one
To a solution of methyl 2-chloro-1-methyl-6-oxo-1, 6-dihydropyridine-3-carboxylate (3.50g,17.4mmol,1.00eq) and glyoxaline hydrochloride (1.64g,17.4mmol,1.00eq) in EtOH (100mL) was added K 2 CO 3 (7.20g,52.1mmol,3.00eq). The reaction mixture was reacted at 90 ℃ for 16 hours and then filtered. The filtrate was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography to give the objective product (500mg,2.48mmol, 14.3% yield).
LC-MS:m/z 192(M+H) + 。
The third step: preparation of 6-bromo-4-hydroxy-2, 8-dimethylpyridin [2,3-d ] pyrimidin-7 (8H) -one
4-hydroxy-2, 8-dimethylpyridine [2,3-d ] at 0 deg.C]To a solution of pyrimidin-7 (8H) -one (700mg,3.66mmol,1.00eq) in DCM (40mL) was added Br 2 (643mg,4.03mmol,208uL,1.10 eq). The reaction mixture was reacted at 25 ℃ for 2 hours and then concentrated under reduced pressure to obtain the objective product (900mg,926umol, 25.3% yield). The product is used for the next reaction without purification.
LC-MS:m/z 270(M+H) + 。
The fourth step: preparation of 6-bromo-4-chloro-2, 8-dimethylpyridin [2,3-d ] pyrimidin-7 (8H) -one
6-bromo-4-hydroxy-2, 8-dimethylpyridine [2,3-d]Pyrimidin-7 (8H) -one (350mg,1.30mmol,1.00eq) in POCl 3 (10mL) the solution was reacted at 110 ℃ for 3h, then concentrated under reduced pressure. The residue was quenched with water (50mL) and extracted with ethyl acetate (100 mL). The combined organic phases were washed with saturated brine, dried and concentrated under reduced pressure to give the desired product (500mg, loud). The product is used in the next reaction without purification.
LC-MS:m/z 288(M+H) + 。
The fifth step: preparation of (R) -6-bromo-2, 8-dimethyl-4- ((1- (3-nitro-5- (trifluoromethyl) phenyl) ethyl) amino) pyridine [2,3-d ] pyrimidin-7 (8H) -one
To a solution of 6-bromo-4-chloro-2, 8-dimethylpyridin [2,3-d ] pyrimidin-7 (8H) -one (0.50g,1.21mmol,1.00eq) and (R) -1- (3-nitro-5- (trifluoromethyl) phenyl) ethan-1-amine (328mg,1.21mmol,1.00eq, HCl) in i-PrOH (10mL) was added DIEA (784mg,6.07mmol,1.06mL,5.00 eq). The reaction solution is reacted for 16h at 80 ℃ and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography to obtain the objective product (0.40g,823umol, 67.8% yield).
LC-MS:m/z 486(M+H) + 。
And a sixth step: preparation of (R) -6-hydroxy-2, 8-dimethyl-4- ((1- (3-nitro-5- (trifluoromethyl) phenyl) ethyl) amino) pyridine [2,3-d ] pyrimidin-7 (8H) -one
(R) -6-bromo-2, 8-dimethyl-4- ((1- (3-nitro-5- (trifluoromethyl) phenyl) ethyl) amino) pyridine [2,3-d ] under nitrogen atmosphere]Dioxane (5mL) of pyrimidin-7 (8H) -one (0.40g,823umol,1.00eq) and H 2 To a solution of O (1mL) were added t-BuXphos (34.9mg, 82.3. mu. mol,0.10eq), KOH (138mg,2.47mmol,3.00eq) and Pd 2 (dba) 3 (75.3mg,82.3umol,0.10 eq). The reaction was reacted at 100 ℃ for 2h and then diluted with water (50mL) and extracted with EtOAc (200 mL). The combined organic phases were washed with saturated brine, dried and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography to obtain the objective product (200mg,472umol, 57.4% yield).
LC-MS:m/z 424(M+H) + 。
The seventh step: preparation of 2, 8-dimethyl-4- (((R) -1- (3-nitro-5- (trifluoromethyl) phenyl) ethyl) amino) -6- (((S) -tetrahydrofuran-3-yl) oxy) pyridin [2,3-d ] pyrimidin-7 (8H) -one
(R) -6-hydroxy-2, 8-dimethyl-4- ((1- (3-nitro-5- (trifluoromethyl) phenyl) ethyl) amino) pyridine [2,3-d]To a solution of pyrimidin-7 (8H) -one (0.19g,449umol,1.00eq) and (R) -tetrahydrofuran-3-yl-4-methylbenzenesulfonate (163mg,673umol,1.50eq) in DMF (3mL) was added Cs 2 CO 3 (439mg,1.35mmol,3.00 eq). The reaction mixture was reacted at 80 ℃ for 2 hours. Then diluted with water (50mL) and extracted with EtOAc (200 mL). The combined organic phases were washed with saturated brine, dried and concentrated under reduced pressure to give the desired product (200mg, loud). The product is used in the next reaction without purification.
LC-MS:m/z 494(M+H) + 。
Eighth step: preparation of 4- (((R) -1- (3-amino-5- (trifluoromethyl) phenyl) ethyl) amino) -2, 8-dimethyl-6- (((S) -tetrahydrofuran-3-yl) oxy) pyridin [2,3-d ] pyrimidin-7 (8H) -one
2, 8-dimethyl-4- (((R) -1- (3-nitro-5- (trifluoromethyl) phenyl) ethyl) amino) -6- (((S) -tetrahydrofuran-3-yl) oxy) pyridine [2,3-d]Pyrimidin-7 (8H) -one (200mg,405umol,1.00eq) in EtOH (5mL) and H 2 To a solution of O (1mL) were added Fe (113mg,2.03mmol,5.00eq) and NH 4 Cl (217mg,4.05mmol,10.0 eq). The reaction solution reacts for 1h at the temperature of 80 DEG CAnd (4) filtering. The filtrate was concentrated under reduced pressure, and the obtained residue was separated by preparative liquid phase to give the objective product (78.0mg,168umol, 41.5% yield).
LC-MS:m/z 464(M+H) + 。 1 HNMR:(400MHz,DMSO-d 6 )δ12.68(br s,1H),7.87(d,J=9.3Hz,1H),6.41(d,J=9.3Hz,1H),3.54(s,3H),2.39(s,3H)。
Example 4 evaluation of biological assays
The following biological test examples further illustrate the present invention, but these examples are not meant to limit the scope of the present invention.
Compound pair KRAS G12C Inhibition assay for binding to SOS 1.
Experimental procedure
(1) Gradient dilution of test compound: 10mM stock solution (dissolved in 100% DMSO) was added to 384 well assay plates to a final DMSO content of 0.25%.
(2) 5ul of Tag1-SOS1 solution was added to the test plate and 5ul of dilution buffer was added to the control.
(4) 5ul of Tag2-KRAS was added to the test plate G12C And (3) solution.
(4) 10ul of Anti-Tag1-Tb3+ and Anti-Tag2-XL665 test solution were added to the test plate. Centrifuged at 1000rpm for 1 min and incubated at room temperature for 2 hr.
(5) Reading board
(6) Finally, IC of the compound was calculated using GraphPad Prism software 50 And (5) obtaining values, and drawing a fitting curve.
KRAS-Compound pairs of examples of the invention G12C The inhibitory activity of the enzyme in combination with SOS1 is shown in Table 1.
Table 1 inhibitory Activity of the Compounds of the examples of the present invention
IC 50 | (nM) |
Example 1 | >10000 |
Example 2 | >10000 |
Example 3 | <100 |
As can be seen from table 1:
EXAMPLES OF THE INVENTION Compound 3 for KRAS G12C The combination with SOS1 showed good inhibitory activity.
Pharmacokinetic testing evaluation
Male SD rats weighing about 220g were fasted overnight and then gavaged with 10mg/kg of a solution of the compound of the present invention [ CMC/TW80 as vehicle ]. Blood was collected at 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 12, and 24 post administration of the compound of the invention, respectively, and the concentration of the compound of the invention in plasma was determined by LC/MS/MS.
The detection result shows that the compound of the invention has good pharmacokinetic property.
Evaluation of antitumor Effect
100uL of the solution containing 5x10 6 The MIA PaCa-2 tumor cell suspension was subcutaneously inoculated into the right posterior abdomen of nude mice. Mice were monitored daily for health and measurements were started when tumors grew to reach. The formula for calculating the tumor volume is 0.5xLxW 2 Wherein L, W represents tumor length and width, respectively. Tumor growth to 150mm 3 Mice were randomly grouped. Mice were gavaged daily with the corresponding dose (15, 50mg/Kg) of CMC-Na suspension of the compound while monitoring their general state. Tumors were measured 3 times per week and body weights were measured twice per week.
The detection result shows that the compound has good anti-tumor effect.
All documents referred to herein are incorporated by reference into this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes or modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the appended claims of the present application.
Claims (10)
1. A compound having the structure of formula (I), a stereoisomer, a tautomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof:
in the formula (I), the compound is shown in the specification,
ring A and ring B are each independently a 5-7 membered ring, and at least one ring atom in ring A or ring B is a heteroatom;
R 1 selected from the group consisting of substituted or unsubstituted: c 3 -C 18 Cycloalkyl, 4-20 membered heterocyclyl, C 6 -C 14 Aryl, 5-14 membered heteroaryl;
R 2 selected from the group consisting of substituted or unsubstituted: c 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl or 4-6 membered heterocyclyl;
r and R', which are identical or different, are each independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, oxo, - (CH) 2 ) m R 8 、-(CH 2 ) m (CH=CH)R 8 、-(CH 2 ) m (C≡C)R 8 、-(CH 2 ) m O(CH 2 ) p R 8 、-(CH 2 ) m SR 8 、-(CH 2 ) m COR 8 、-(CH 2 ) m C(O)OR 8 、-(CH 2 ) m S(O) q R 8 、-(CH 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m S(O) q NR 8 R 9 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In which CH 2 H in (a) may be optionally substituted;
R 8 、R 9 and R 10 Each independently selected from the group consisting of substituted or unsubstituted: hydrogen, C 1 -C 18 Alkyl radical, C 3 -C 20 Cycloalkyl, 4-20 membered heterocyclyl, R 11 -(C 3 -C 20 Cycloalkylene radical C 1 -C 18 Alkylene) -, R 11 - (4-to 20-membered heterocycloalkylene C) 1 -C 18 Alkylene) -, - (C) 3 -C 20 Cycloalkylene radical C 1 -C 18 Alkylene) -R 11 - (4-to 20-membered heterocycloalkylene C) 1 -C 18 Alkylene) -R 11 ;
Or in- (CH) 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m S(O) q NR 8 R 9 In, R 8 And R 9 And the adjacent N atom thereof form a substituted or unsubstituted 4-8 membered heterocyclic group; or in- (CH) 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In, R 8 And R 9 Is cyclized with its adjacent N atom to form a substituted or unsubstituted 4-8 membered heterocyclic group, or R 8 And R 10 Ring-closing with its adjacent atom to form a substituted or unsubstituted 4-8 membered heterocyclic group;
R 11 selected from: hydrogen, deuterium, C 1 -C 18 Alkyl, deuterated C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl hydroxy, C 3 -C 20 Cycloalkyl, C 1 -C 18 Alkoxy, deuterated C 1 -C 18 Alkoxy, halo C 1 -C 18 Alkoxy radical, C 3 -C 20 Cycloalkyl oxy, C 6 -C 14 Aryl, 5-14 membered heteroaryl, 4-20 membered heterocyclyl, C 6 -C 14 Aryloxy, 5-14 membered heteroaryloxy, 4-20 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea;
wherein the above substitution means substitution with one or more groups selected from the group consisting of: hydrogen, deuterium, C 1 -C 18 Alkyl, deuterated C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl hydroxy, C 3 -C 20 Cycloalkyl radical, C 1 -C 18 Alkoxy, deuterated C 1 -C 18 Alkoxy, halo C 1 -C 18 Alkoxy radical, C 3 -C 20 Cycloalkyloxy radical, C 6 -C 14 Aryl, 5-14 membered heteroaryl, 4-20 membered heterocyclyl, C 6 -C 14 Aryloxy, 5-14 membered heteroaryloxy, 4-20 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea;
m is 0, 1,2,3,4, 5 or 6;
p is 0, 1,2,3,4, 5 or 6;
q is 1 or 2;
u is 0, 1,2 or 3;
t is 0, 1,2,3 or 4;
2. The compound of claim 1, a stereoisomer, a tautomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof, having the structure of formula (Γ):
in the formula (I), the compound is shown in the specification,
R 1 selected from the group consisting of substituted or unsubstituted: c 3 -C 18 Cycloalkyl, 4-20 membered heterocyclyl, C 6 -C 14 Aryl, 5-14 membered heteroaryl;
R 2 selected from the group consisting of substituted or unsubstituted: c 1 -C 6 Alkyl radical, C 3 -C 6 Cycloalkyl or 4-6 membered heterocyclyl;
X 1 、X 2 、X 3 、X 4 、X 5 、X 6 、X 7 、X 8 and X 9 Each independently selected from: C. CR 3 、CO、N、NR 4 、SO 2 Or CR 3 R 5 (ii) a Wherein, X 1 、X 2 、X 3 、X 4 、X 5 、X 6 、X 7 、X 8 And X 9 At least one of which contains a heteroatom;
R 3 the same or different, each independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, - (CH) 2 ) m R 8 、-(CH 2 ) m (CH=CH)R 8 、-(CH 2 ) m (C≡C)R 8 、-(CH 2 ) m O(CH 2 ) p R 8 、-(CH 2 ) m SR 8 、-(CH 2 ) m COR 8 、-(CH 2 ) m C(O)OR 8 、-(CH 2 ) m S(O) q R 8 、-(CH 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m S(O) q NR 8 R 9 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In which CH 2 H in (a) may be optionally substituted;
R 5 the same or different, each independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, - (CH) 2 ) m R 8 、-(CH 2 ) m (CH=CH)R 8 、-(CH 2 ) m (C≡C)R 8 、-(CH 2 ) m O(CH 2 ) p R 8 、-(CH 2 ) m SR 8 、-(CH 2 ) m COR 8 、-(CH 2 ) m C(O)OR 8 、-(CH 2 ) m S(O) q R 8 、-(CH 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m S(O) q NR 8 R 9 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In which, CH 2 H in (a) may be optionally substituted;
R 4 the same or different, each independently selected from the group consisting of: hydrogen, deuterium, - (CH) 2 ) m R 8 、-(CH 2 ) m (CH=CH)R 8 、-(CH 2 ) m (C≡C)R 8 、-(CH 2 ) m O(CH 2 ) p R 8 、-(CH 2 ) m SR 8 、-(CH 2 ) m COR 8 、-(CH 2 ) m C(O)OR 8 、-(CH 2 ) m S(O) q R 8 、-(CH 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m S(O) q NR 8 R 9 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In which CH 2 H in (a) may be optionally substituted;
R 8 、R 9 and R 10 Each independently selected from the group consisting of substituted or unsubstituted: hydrogen, C 1 -C 18 Alkyl radical, C 3 -C 20 Cycloalkyl, 4-20 membered heterocyclyl, R 11 -(C 3 -C 20 Cycloalkylene radical C 1 -C 18 Alkylene) -, R 11 - (4-to 20-membered heterocycloalkylene C) 1 -C 18 Alkylene) -, - (C) 3 -C 20 Cycloalkylene radical C 1 -C 18 Alkylene) -R 11 - (4-to 20-membered heterocycloalkylene C) 1 -C 18 Alkylene) -R 11 ;
Or in- (CH) 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m S(O) q NR 8 R 9 In, R 8 And R 9 And the adjacent N atom thereof form a substituted or unsubstituted 4-8 membered heterocyclic group; or in- (CH) 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In, R 8 And R 9 Is cyclized with its adjacent N atom to form a substituted or unsubstituted 4-8 membered heterocyclic group, or R 8 And R 10 Ring-closing with its adjacent atom to form a substituted or unsubstituted 4-8 membered heterocyclic group;
R 11 selected from: hydrogen, deuterium, C 1 -C 18 Alkyl, deuterated C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl hydroxy, C 3 -C 20 Cycloalkyl radical, C 1 -C 18 Alkoxy, deuterated C 1 -C 18 Alkoxy, halo C 1 -C 18 Alkoxy radical, C 3 -C 20 Cycloalkyl oxy, C 6 -C 14 Aryl, 5-14 membered heteroaryl, 4-20 membered heterocyclyl, C 6 -C 14 Aryloxy, 5-14 membered heteroaryloxy, 4-20 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea;
wherein the above-mentioned substitution means substitution by one or more groups selected from the group consisting of: hydrogen, deuterium, C 1 -C 18 Alkyl, deuterated C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl hydroxy, C 3 -C 20 Cycloalkyl, C 1 -C 18 Alkoxy, deuterated C 1 -C 18 Alkoxy, halo C 1 -C 18 Alkoxy radical, C 3 -C 20 Cycloalkyl oxy, C 6 -C 14 Aryl, 5-14 membered heteroaryl, 4-20 membered heterocyclyl, C 6 -C 14 Aryloxy, 5-14 membered heteroaryloxy, 4-20 membered heterocyclyloxy, halogen, oxo, nitro, hydroxy, cyano, ester, amine, amide, sulfonamide, or urea;
m is 0, 1,2,3,4, 5 or 6;
p is 0, 1,2,3,4, 5 or 6;
q is 1 or 2;
4. The compound, stereoisomer, tautomer, crystalline form, pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof according to any one of claims 2 to 3,moieties are selected from:
in the formula (I), the compound is shown in the specification,
R 3a -R 3f the same or different, each independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, - (CH) 2 ) m R 8 、-(CH 2 ) m (CH=CH)R 8 、-(CH 2 ) m (C≡C)R 8 、-(CH 2 ) m O(CH 2 ) p R 8 、-(CH 2 ) m SR 8 、-(CH 2 ) m COR 8 、-(CH 2 ) m C(O)OR 8 、-(CH 2 ) m S(O) q R 8 、-(CH 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m S(O) q NR 8 R 9 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In which CH 2 H in (a) may be optionally substituted;
R 4a -R 4b identical or different, each independently selected from the group consisting of: hydrogen, deuterium, - (CH) 2 ) m R 8 、-(CH 2 ) m (CH=CH)R 8 、-(CH 2 ) m (C≡C)R 8 、-(CH 2 ) m O(CH 2 ) p R 8 、-(CH 2 ) m SR 8 、-(CH 2 ) m COR 8 、-(CH 2 ) m C(O)OR 8 、-(CH 2 ) m S(O) q R 8 、-(CH 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m S(O) q NR 8 R 9 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In which CH 2 H in (a) may be optionally substituted;
R 5b -R 5c the same or different, each independently selected from the group consisting of: hydrogen, deuterium, halogen, cyano, - (CH) 2 ) m R 8 、-(CH 2 ) m (CH=CH)R 8 、-(CH 2 ) m (C≡C)R 8 、-(CH 2 ) m O(CH 2 ) p R 8 、-(CH 2 ) m SR 8 、-(CH 2 ) m COR 8 、-(CH 2 ) m C(O)OR 8 、-(CH 2 ) m S(O) q R 8 、-(CH 2 ) m NR 8 R 9 、-(CH 2 ) m C(O)NR 8 R 9 、-(CH 2 ) m NR 8 C(O)R 9 、-(CH 2 ) m NR 8 C(O)NR 9 R 10 、-(CH 2 ) m S(O) q NR 8 R 9 、-(CH 2 ) m NR 8 S(O) q R 9 、-(CH 2 ) m NR 8 S(O) q NR 9 R 10 In which, CH 2 H in (a) may be optionally substituted;
wherein the above substitution means substitution by a group selected from the group consisting of: hydrogen, deuterium, C 1 -C 18 Alkyl, deuterated C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl, halo C 1 -C 18 Alkyl hydroxy, C 3 -C 20 Cycloalkyl radical, C 1 -C 18 Alkoxy, deuterated C 1 -C 18 Alkoxy, halo C 1 -C 18 Alkoxy radical, C 3 -C 20 Cycloalkyloxy radical, C 6 -C 14 Aryl, 5-14 membered heteroaryl, 4-20 membered heterocyclyl, C 6 -C 14 Aryloxy, 5-14 membered heteroarylAn acyloxy group, a 4-20 membered heterocyclyloxy group, a halogen, an oxo group, a nitro group, a hydroxyl group, a cyano group, an ester group, an amine group, an amide group, a sulfonamide group, or a urea group;
wherein R is 8 、R 9 、R 10 M, p and q are as defined in claim 1.
7. a process for the preparation of a compound of formula (I), a stereoisomer, a tautomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof, according to claim 1, characterized by the steps of:
(i) reacting a compound of formula V-1 with a compound of formula V-2 in an inert solvent in the presence of a base, a condensing agent or a Pd catalyst to obtain a compound of formula (I);
in the formula (I), the compound is shown in the specification,
x is selected from: halogen, OH, O, OTf, OTs, Oms;
R 1 、R 2 r, R', ring A, ring B, u and t are as defined in claim 1.
8. A pharmaceutical composition comprising i) one or more compounds of any one of claims 1-6, stereoisomers, tautomers, crystalline forms, pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof; and ii) a pharmaceutically acceptable carrier.
9. Use of a compound according to any one of claims 1 to 6, a stereoisomer, a tautomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof, or a pharmaceutical composition according to claim 8, for the preparation of a medicament for the prophylaxis and/or treatment of a disease associated with i) SOS1 activity or expression; and/or ii) SOS1 downstream signal pathway related diseases.
10. A method of inhibiting SOS1 activity in vitro comprising the steps of: contacting a compound of any one of claims 1-6, a stereoisomer, a tautomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof, or a pharmaceutical composition of claim 8, with a protein or a cell, thereby inhibiting SOS1 activity.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110257196.2A CN115043842A (en) | 2021-03-09 | 2021-03-09 | Amino-substituted bicyclic inhibitor and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110257196.2A CN115043842A (en) | 2021-03-09 | 2021-03-09 | Amino-substituted bicyclic inhibitor and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115043842A true CN115043842A (en) | 2022-09-13 |
Family
ID=83156363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110257196.2A Pending CN115043842A (en) | 2021-03-09 | 2021-03-09 | Amino-substituted bicyclic inhibitor and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115043842A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114685487A (en) * | 2020-12-27 | 2022-07-01 | 上海凌达生物医药有限公司 | Pyrimidine heterocyclic compound, preparation method and application |
CN115417868A (en) * | 2021-09-13 | 2022-12-02 | 石药集团中奇制药技术(石家庄)有限公司 | Heterocyclic compound with antitumor activity and application thereof |
WO2023051628A1 (en) * | 2021-09-29 | 2023-04-06 | 上海海和药物研究开发股份有限公司 | Sos1 inhibitors having pyrido six-membered ring structure |
WO2023051635A1 (en) * | 2021-09-28 | 2023-04-06 | 上海艾力斯医药科技股份有限公司 | Fused ring compound, and preparation method therefor and use thereof |
WO2023116902A1 (en) * | 2021-12-23 | 2023-06-29 | 北京望实智慧科技有限公司 | Sos1 inhibitor |
WO2023179567A1 (en) * | 2022-03-22 | 2023-09-28 | 上海维申医药有限公司 | Pyrimido-pyridazinone compound as toll-like receptor agonist |
WO2024027762A1 (en) * | 2022-08-05 | 2024-02-08 | 上海艾力斯医药科技股份有限公司 | Fused ring compound, and preparation method therefor and use thereof |
-
2021
- 2021-03-09 CN CN202110257196.2A patent/CN115043842A/en active Pending
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114685487A (en) * | 2020-12-27 | 2022-07-01 | 上海凌达生物医药有限公司 | Pyrimidine heterocyclic compound, preparation method and application |
CN114685487B (en) * | 2020-12-27 | 2024-04-19 | 上海凌达生物医药有限公司 | Pyrimidine heterocyclic compounds, preparation method and application |
CN115417868A (en) * | 2021-09-13 | 2022-12-02 | 石药集团中奇制药技术(石家庄)有限公司 | Heterocyclic compound with antitumor activity and application thereof |
CN115417868B (en) * | 2021-09-13 | 2024-04-02 | 石药集团中奇制药技术(石家庄)有限公司 | Heterocyclic compound with antitumor activity and application thereof |
WO2023051635A1 (en) * | 2021-09-28 | 2023-04-06 | 上海艾力斯医药科技股份有限公司 | Fused ring compound, and preparation method therefor and use thereof |
WO2023051628A1 (en) * | 2021-09-29 | 2023-04-06 | 上海海和药物研究开发股份有限公司 | Sos1 inhibitors having pyrido six-membered ring structure |
WO2023116902A1 (en) * | 2021-12-23 | 2023-06-29 | 北京望实智慧科技有限公司 | Sos1 inhibitor |
WO2023179567A1 (en) * | 2022-03-22 | 2023-09-28 | 上海维申医药有限公司 | Pyrimido-pyridazinone compound as toll-like receptor agonist |
WO2024027762A1 (en) * | 2022-08-05 | 2024-02-08 | 上海艾力斯医药科技股份有限公司 | Fused ring compound, and preparation method therefor and use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115175908B (en) | Aryl or heteroaryl pyridone or pyrimidinone derivatives, and preparation method and application thereof | |
CN115043842A (en) | Amino-substituted bicyclic inhibitor and preparation method and application thereof | |
CN113666923A (en) | Alkoxy alkyl substituted heterocyclic inhibitor and preparation method and application thereof | |
WO2022017533A1 (en) | Compound useful as cdk7 kinase inhibitor and use thereof | |
CN112694475A (en) | Cycloalkyl and heterocycloalkyl inhibitors, and preparation method and application thereof | |
RU2633694C2 (en) | Dyetherned phenylaminopyrimidine and pharmaceutical composition containing such connection | |
CN114835719A (en) | Substituted bicyclic aromatic heterocyclic amine inhibitor and preparation method and application thereof | |
CN115109078A (en) | Pyrimidopyridine inhibitor and preparation method and application thereof | |
CN112778301A (en) | Tetrahydropyridopyrimidine inhibitor and preparation method and application thereof | |
CN114835703A (en) | Substituted pyrimidopyridone inhibitor and preparation method and application thereof | |
CN113105448A (en) | Aryl or heteroaryl pyridone or pyrimidone derivative and preparation method and application thereof | |
CN114437077B (en) | Compounds useful as kinase inhibitors and uses thereof | |
CN112824410A (en) | Aza-heptacyclic inhibitor and preparation method and application thereof | |
WO2022188819A1 (en) | Sos1 proteolysis modulator, preparation method therefor and application thereof | |
CN112867717A (en) | Compounds useful as kinase inhibitors and uses thereof | |
CN113045569B (en) | Compounds useful as RET kinase inhibitors and uses thereof | |
CN116332959A (en) | KRAS G12D Proteolytic regulator and its prepn and application | |
CN113801113A (en) | Aryl or heteroaryl pyridone or pyrimidone derivative and preparation method and application thereof | |
CN114437075A (en) | Compounds useful as inhibitors of NTRK kinase and uses thereof | |
CN115215844A (en) | Substituted pyrimido-ring inhibitor and preparation method and application thereof | |
CN115215869A (en) | Substituted tricyclic inhibitor and preparation method and application thereof | |
CN114380805A (en) | Substituted benzo or pyrido pyrimidine amine inhibitor and preparation method and application thereof | |
CN114671866A (en) | Aryl or heteroaryl pyridone or pyrimidone derivative and preparation method and application thereof | |
CN112574255A (en) | Organic arsine-based CDK inhibitor and preparation method and application thereof | |
CN114907324A (en) | Substituted benzo or pyrido pyrimidine amine inhibitor and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |